Aytu BioPharma (AYTU) 10-K 12 Oct 23 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Sep. 20, 2023	Dec. 30, 2022
Cover [Abstract]
Entity Central Index Key	0001385818
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-38247
Entity Registrant Name	AYTU BIOPHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0883144
Entity Address, Address Line One	7900 East Union Avenue
Entity Address, Address Line Two	Suite 920
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80237
City Area Code	720
Local Phone Number	437-6580
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Listing, Par Value Per Share	$ 0.0001
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float					$ 12.3
Entity Common Stock, Shares Outstanding				5,530,027
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	Grant Thornton, LLP	Plante & Moran, PLLC	Plante & Moran, PLLC
Auditor Firm ID	248	166	166
Auditor Location	Denver, Colorado	Denver, Colorado	Denver, Colorado

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Current assets
Cash and cash equivalents	$ 22,985	$ 19,360
Accounts receivable, net	28,937	21,712
Inventories	11,995	10,849
Prepaid expenses	8,047	7,375
Other current assets	868	633
Total current assets	72,832	59,929
Property and equipment, net	1,815	3,025
Operating lease right-of-use asset	2,054	3,271
Intangible assets, net	58,970	70,632
Other non-current assets	792	766
Total non-current assets	63,631	77,694
Total assets	136,463	137,623
Current liabilities
Accounts payable and other	13,478	10,987
Accrued liabilities	46,799	44,187
Short-term line of credit	1,563	3,813
Current portion of debt	85	96
Other current liabilities	7,090	5,359
Total current liabilities	69,015	64,442
Debt, net of current portion	14,713	14,279
Derivative warrant liabilities	6,403	1,796
Other non-current liabilities	6,975	12,798
Total liabilities	97,106	93,315
Commitments and contingencies (Note 18)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of June 30, 2023 and June 30, 2022
Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 5,517,174 and 1,928,941, respectively, as of June 30, 2023 and June 30, 2022	1
Additional paid-in capital	343,485	331,386
Accumulated deficit	(304,129)	(287,078)
Total stockholders' equity	39,357	44,308
Total liabilities and stockholders' equity	$ 136,463	$ 137,623

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Jun. 30, 2022
Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	5,517,174	1,928,941
Common stock, shares outstanding (in shares)	5,517,174	1,928,941

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Consolidated Statements of Operations
Product revenue, net	$ 107,399	$ 96,669
Revenue from Contract with Customer, Product and Service	Product	Product
Cost of sales	$ 40,767	$ 44,386
Cost, Product and Service	Product	Product
Gross profit	$ 66,632	$ 52,283
Operating expenses
Selling and marketing	41,448	38,713
General and administrative	28,630	31,167
Research and development	4,095	12,662
Impairment of goodwill		65,802
Impairment of other assets	5,705	9,656
Amortization of intangible assets	4,788	5,844
Gain from contingent consideration	(969)	(1,655)
Total operating expenses	83,697	162,189
Loss from operations	(17,065)	(109,906)
Other income (expense)
Other expense, net	(4,779)	(757)
Gain on extinguishment of debt		169
Gain on derivative warrant liability	4,793	1,605
Total other income, net	14	1,017
Loss before income tax	(17,051)	(108,889)
Income tax benefit	0	(110)
Net loss	$ (17,051)	$ (108,779)
Weighted average number of common shares outstanding - basic (in shares)	3,339,906	1,469,875
Weighted average number of common shares outstanding - diluted (in shares)	3,339,906	1,469,875
Basic net loss per common share (in dollars per share)	$ (5.11)	$ (74.01)
Diluted net loss per common share (in dollars per share)	$ (5.11)	$ (74.01)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Jun. 30, 2021		$ 315,867	$ (178,299)	$ 137,568
Beginning balance (in shares) at Jun. 30, 2021	1,374,521
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		5,248		5,248
Stock-based compensation (in shares)	20,434
Issuance of common stock, net of issuance costs		8,854		8,854
Issuance of common stock, net of issuance costs (in shares)	424,539
Issuance of common stock related to milestone payment		1,425		1,425
Issuance of common stock related to milestone payment (in shares)	109,447
Tax withholding for stock-based compensation		(8)		(8)
Net loss			(108,779)	(108,779)
Ending balance at Jun. 30, 2022		331,386	(287,078)	$ 44,308
Ending balance (in shares) at Jun. 30, 2022	1,928,941			1,928,941
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		6,046		$ 6,046
Stock-based compensation (in shares)	(18,180)
Issuance of common stock, net of issuance costs	$ 1	6,053		6,054
Issuance of common stock, net of issuance costs (in shares)	3,606,413
Net loss			(17,051)	(17,051)
Ending balance at Jun. 30, 2023	$ 1	$ 343,485	$ (304,129)	$ 39,357
Ending balance (in shares) at Jun. 30, 2023	5,517,174			5,517,174

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement of Stockholders' Equity [Abstract]
Stock issued during period, value, new issues, issuance costs	$ 1,004	$ 1,048

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating Activities
Net loss	$ (17,051)	$ (108,779)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	8,815	10,146
Impairment expense	5,705	75,458
Inventory write-down	2,351	2,186
Stock-based compensation expense	6,046	5,248
Gain on derivative warrant liability	(4,793)	(1,605)
Gain from contingent consideration	(969)	(1,655)
Amortization of senior debt (premium) discount	559	(126)
Shares issuance related to milestone payment		1,425
Gain on debt extinguishment		(193)
Other noncash adjustments	7	(65)
Changes in operating assets and liabilities:
Accounts receivable	(7,153)	6,533
Inventory	(3,609)	1,299
Prepaid expenses and other current assets	(914)	2,228
Accounts payable and other	2,384	(7,681)
Accrued liabilities	3,605	(13,292)
Other operating assets and liabilities, net	(111)	50
Net cash used in operating activities	(5,129)	(28,823)
Investing Activities
Contingent consideration payment	(5)	(3,178)
Other investing activities	(112)	(70)
Net cash used in investing activities	(117)	(3,248)
Financing Activities
Net proceeds from issuance of stock	15,575	11,694
Payment made to fixed payment arrangement	(4,266)	(4,409)
Net payments made on short-term line of credit	(2,250)	(4,121)
Payments made to borrowings	(96)	(16,101)
Proceeds from borrowings		15,000
Payment for debt issuance costs	(92)	(526)
Other financing activities		(7)
Net cash provided by financing activities	8,871	1,530
Net change in cash and cash equivalents	3,625	(30,541)
Cash and cash equivalents at beginning of period	19,360	49,901
Cash and cash equivalents at end of period	22,985	19,360
Supplemental cash flow data
Cash paid for interest	3,812	3,148
Non-cash investing and financing activities:
Other noncash investing and financing activities	$ 147	$ 54

Nature of Business and Financia

Nature of Business and Financial Condition	12 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Financial Condition	1. Nature of Business and Financial Condition Aytu BioPharma, Inc. (“Aytu,” or the “Company”), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products. The Company operates through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health Segment, which consists of various consumer healthcare products (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, (the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc. On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty The Rx Segment primarily consists of two product portfolios: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”) together the “ADHD Portfolio”, and the “Pediatric Portfolio” consisting of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions. The Consumer Health Portfolio consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, urological health and general wellness, commercialized through direct mail and e-commerce marketing channels. The Company’s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team’s expertise to build leading brands within large therapeutic and consumer markets. As a result of focusing on building the portfolio of revenue-generating products, the Company has indefinitely suspended active development of its clinical development program AR101 (enzastaurin), and has terminated the license agreements relating to Healight and NT0502 (N-desethyloxybutynin). As of June 30, 2023, the Company had $23.0 million of cash and cash equivalents and $28.9 million in accounts receivable. The Company incurred a net loss of $17.1 million and $108.8 million during the years ended June 30, 2023 and 2022, respectively. The Company had an accumulated deficit of $304.1 million and $287.1 million as of June 30, 2023 and 2022, respectively. Cash used in operations was $5.1 million and $28.8 million during the years ended June 30, 2023 and 2022, respectively. In addition, the Company has non-operating liabilities that are scheduled to, or may become current in the eighteen months following the filing of this 10-K, most notably the maturity of the $15 million Avenue Capital term note (the “Avenue Note”). The Company expects to refinance the Avenue Note in the event it does not have sufficient cash on hand to retire it. As a result, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on i) eliminating expenses for clinical development, ii) winding down or monetizing the Consumer Health Segment, which has generated negative cash flows since its acquisition in 2021, iii) refinancing its $15 million Avenue Note (see Note 11 – Long-term Debt) to extend its maturity date, and, if necessary iv) raising additional capital through public or private equity, debt offerings, or monetizing additional assets in order to meet its obligations. Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it may be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principals of Consolidation . Basis of Presentation . Use of estimates . Prior Period Reclassification . Previously Reported Financial Statements . SEC Staff Accounting Bulletin No. 99, “Materiality,” and the Financial Accounting Standards Board (“FASB”), Statement of Financial Accounting Concepts No. 2 “Qualitative Characteristics of Accounting Information” indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the consolidated financial statements as of and for the fiscal year ended June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to this period for comparative purposes. The adjustments did not change the Company’s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations. The consolidated financial statements as of and for the fiscal year ended June 30, 2022 have been adjusted as shown in the following tables. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Balance Sheet data ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ $ - ​ $ 1,796 ​ $ 1,796 Total liabilities ​ $ 91,531 ​ $ 1,784 ​ $ 93,315 Additional paid-in capital ​ $ 334,560 ​ $ (3,174) ​ $ 331,386 Accumulated deficit ​ $ (288,472) ​ $ 1,394 ​ $ (287,078) Total stockholders’ equity ​ $ 46,092 ​ $ (1,784) ​ $ 44,308 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Twelve Months Ended ​ ​ June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liability ​ $ 211 ​ $ 1,394 ​ $ 1,605 Total other income, net (1) ​ $ 1,278 ​ $ (261) ​ $ 1,017 Loss before income tax ​ $ (110,283) ​ $ 1,394 ​ $ (108,889) Net loss ​ $ (110,173) ​ $ 1,394 ​ $ (108,779) Basic and diluted net loss per common share ​ $ (75.00) ​ $ 0.99 ​ $ (74.01) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Issuance of common stock, net of issuance cost ​ $ 11,652 ​ $ (2,798) ​ $ 8,854 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flow data ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (110,173) ​ $ 1,394 ​ $ (108,779) Gain on derivative warrant liability ​ $ (211) ​ $ (1,394) ​ $ (1,605) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1) Includes reclassification of gain or loss from the fair value of contingent consideration. See Prior Period Reclassification in Note 2 – Summary of Significant Accounting Policies. Previously Reported Segment Information . Cash and Cash Equivalents . Accounts Receivable, net . million for both years ended June 30, 2023 and 2022. The table below presents the opening and closing balances of receivables from customers. ​ ​ ​ ​ ​ ​ ​ ​ Accounts Receivable, gross ​ ​ ​ (in thousands) Opening balance, June 30, 2022 ​ $ 24,219 Closing balance, June 30, 2023 ​ ​ 31,927 Increase ​ $ 7,708 ​ ​ ​ ​ Opening balance, June 30, 2021 ​ $ 30,325 Closing balance, June 30, 2022 ​ ​ 24,219 Decrease ​ $ (6,106) ​ ​ ​ ​ ​ The table below details the change in allowance for discount, and allowance for chargeback for the periods presented. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for Discount ​ ​ Allowance for Chargeback ​ ​ Total Allowance ​ ​ ​ (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance, June 30, 2021 ​ $ 1,133 ​ $ 1,016 ​ $ 2,149 Charges to expense ​ ​ 6,760 ​ ​ 4,598 ​ ​ 11,358 Payments ​ ​ (6,592) ​ ​ (4,408) ​ ​ (11,000) Balance, June 30, 2022 ​ $ 1,301 ​ $ 1,206 ​ $ 2,507 Charges to expense ​ ​ 9,074 ​ ​ 4,554 ​ ​ 13,628 Payments ​ ​ (8,597) ​ ​ (4,548) ​ ​ (13,145) Balance, June 30, 2023 ​ $ 1,778 ​ $ 1,212 ​ $ 2,990 ​ Inventories . The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified. Going Concern Determination . Property and equipment, net . Furniture equipment two shorter of the estimated useful life Leases . Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company’s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company’s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less. Operating leases are included in other liabilities in the Company’s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company’s consolidated balance sheets. Income from subleasing is recognized on a straight-line basis over the sublease term, subject to collectability issues which will limit the income recognized to payment received until collectability is no longer an issue. Any variable payments are recognized as incurred. Fair Value of Financial Instruments Acquisitions . Warrants. Revenue Recognition . Segment”). The Company evaluates its contracts with customers to determine revenue recognition using the following five-step model: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) a performance obligation is satisfied. There is not a recognized financing component related to product sales. Rx Segment Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally “free-on-board” destination when shipped domestically within the United States and “free-on-board” shipping point when shipped internationally consistent with the contractual terms. Rx product revenue is recognized net of consideration paid to the Company’s customers and other adjustments to the transaction price (known as “Gross to Net” adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions. The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as “Gross to Net” adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. The Gross to Net adjustments include: ● Savings offers The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. ● Prompt payment discounts Prompt payment discounts are based on standard provisions of wholesalers’ services. ● Wholesale distribution fees Wholesale distribution fees are based on definitive contractual agreements for the management of the Company’s products by wholesalers. ● Rebates The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. ● Wholesaler chargebacks The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers’ end customers. ● Returns Wholesalers’ contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate. Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do not believe variances between actual and estimated amounts have been material. Consumer Health Segment The Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) is from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales. Customer Contract Costs . Concentration of Credit Risk . The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions. The Company is also subject to credit risk from accounts receivable related to product sales. The Company’s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company’s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company’s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally forty The following table presents customers that contributed more than 10% of gross revenue and accounts receivable : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of gross revenue ​ Percentage of accounts receivable ​ ​ June 30, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 Customer A ​ 43 % ​ 41 % ​ 50 % ​ 52 % Customer B ​ 18 % ​ 20 % ​ 19 % ​ 25 % Customer C ​ 17 % ​ 18 % ​ 14 % ​ 18 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Costs of Sales . Stock-Based Compensation . Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company’s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the “simplified method,” which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn’t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur. Research and Development Intangible Assets . Impairment of Long-lived Assets and Goodwill . Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company’s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company’s outlook and market performance of the Company’s industry forecasted financial performance indicate that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company’s industry. Contingent consideration . . Advertising Costs . Income Taxes . balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations. Debt issuance costs, discounts (premiums) . Segment information . Paragraph IV litigation costs . Business Combination and Contingent considerations . The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income. Net Loss Per Common Share . The following table sets-forth securities excluded from the calculation of diluted earnings per share. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2023 2022 Warrant to purchase common stock (Note 16) ​ 6,538,052 434,328 Employee stock options (Note 15) ​ 52,762 3,899 Employee unvested restricted stock (Note 15) ​ 40,996 85,377 Employee unvested restricted stock units ​ (Note 15) ​ 4,963 ​ 8,500 Total ​ ​ ​ 6,636,773 532,104 ​ Recently Adopted Accounting Pronouncements Reference Rate Reform. Reference Rate Reform (Topic 848) “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” Earnings Per Share. “Earnings Per Share (Topic260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options”. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” Financial Instruments – Credit Losses upon adoption of the new credit losses standard. The effective dates and transition for ASU 2019-05 aligns with those of ASU 2016-13. In March 2022, the FASB issued ASU 2022-02, “ Financial Instruments – Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	12 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	3. Revenues from Contracts with Customers The Company disaggregates its revenue into two segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys XR-ODT and Cotempla XR-ODT; and the Pediatric Portfolio, comprised of Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER. The Consumer Health portfolio is comprised of over ten consumer health products competing in large healthcare categories. Revenues by Segment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2023 2022 ​ ​ (In thousands) Rx Segment $ 73,799 $ 61,121 Consumer Health Segment ​ ​ 33,600 ​ ​ 35,548 Consolidated revenue $ 107,399 $ 96,669 ​ Revenues by Product Portfolio ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2023 2022 Rx Segment ​ (In thousands) ADHD ​ $ 46,855 ​ $ 42,855 Pediatric ​ ​ 25,377 ​ ​ 16,084 Other ​ ​ 1,567 ​ ​ 2,182 ​ ​ $ 73,799 ​ $ 61,121 ​ Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio. Revenues by Geographic location. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2023 2022 ​ ​ (In thousands) U.S. ​ $ 106,918 ​ $ 94,606 International ​ 481 ​ 2,063 Total net revenue ​ $ 107,399 ​ $ 96,669 ​

Inventories

Inventories	12 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ (In thousands) Raw materials $ 1,301 $ 1,814 Work in process ​ ​ 2,956 ​ ​ 1,838 Finished goods ​ 7,738 ​ 7,197 Inventories ​ $ 11,995 ​ $ 10,849 ​ ​ The Company incurred charges of $2.4 million and $4.2 million to reduce the carrying value of inventory to net realizable value during the years ended June 30, 2023 and 2022, respectively, primarily as a result of unsalable and slow-moving products.

Property and Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment, net consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,433 $ 2,487 Leasehold improvements 999 ​ 999 Office equipment, furniture and other 1,125 ​ 1,128 Lab equipment 832 ​ 832 Assets under construction 107 ​ — Property and equipment, gross ​ ​ 5,496 ​ ​ 5,446 Less accumulated depreciation and amortization ​ ​ (3,681) ​ ​ (2,421) Property and equipment, net $ 1,815 ​ $ 3,025 ​ ​ Depreciation expense was $1.3 million and $1.6 million for the years ended June 30, 2023 and 2022, respectively. During the year ended June 30, 2022, the Company recognized a gain of $0.1 million on the disposal of equipment. During the year ended June 30, 2022, in connection with the decision to divest Tussionex, the Company recorded a $0.2 million impairment

Leases

Leases	12 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	6. Leases The Company’s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases are for equipment. These leases have original lease periods expiring between 2022 and 2027. Most leases include option provisions under which the parties may extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $3.5 million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does not provide an implicit rate, a borrowing rate of 6.7% was used to determine the present value of future lease payments. The finance leases are related to equipment finance leases with fixed contract terms and an implicit interest rate of approximately 5.9%. In April 2023, the Company entered into an agreement with a manufacturing company to sublease 22,909 square feet of the Company’s manufacturing facility in Grand Prairie, Texas (the “Sublease Agreement”). The sublease commenced in May 2023 and will terminate on December 31, 2024. The Sublease Agreement provides the sublessee an option to expand the subleased property to include the remaining 54,203 square feet of the Company’s manufacturing facility. The expansion date may commence as early as April 1, 2024 but no later than December 31, 2024 (the “Expansion Date”). Under the terms of the Sublease Agreement, the sublessee will pay base rent of approximately $20,500 per month through the Expansion Date. Beginning on the Expansion Date, base rent will be $70,686 per month through the expiration of the sublease. In addition to the base rent, the sublessee will pay the Company certain operating expenses incurred by the Company. During the fiscal year ended June 30, 2023, in addition to the sublease mentioned above, the Company entered into an operating lease agreement to relocate its principal office (See Note 18 – Commitments and Contingencies). During the fiscal year ended June 30, 2022, the Company commenced a five-year operating lease and recorded an ROU of $0.3 million. The components of lease expenses are as follows; ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ ​ ​ June 30, ​ ​ ​ 2023 2022 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 1,402 ​ $ 1,299 Operating expenses Short-term lease cost ​ 97 ​ 152 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets ​ 66 ​ 73 Cost of sales Interest on lease liabilities ​ ​ 9 ​ ​ 14 ​ Other (expense), net Total net lease cost ​ $ 1,574 ​ $ 1,538 ​ Supplemental balance sheet information related to leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, Balance Sheet Classification ​ ​ 2023 ​ 2022 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 2,054 ​ $ 3,271 Operating lease right-of-use asset Finance lease assets ​ ​ 159 ​ 256 Property and equipment, net Total leased assets ​ $ 2,213 ​ $ 3,527 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,258 ​ $ 1,227 ​ Other current liabilities Finance leases ​ ​ 85 ​ ​ 96 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 832 ​ ​ 2,090 ​ Other liabilities Finance leases ​ ​ — ​ ​ 84 ​ Debt, net of current portion Total lease liabilities ​ $ 2,175 ​ $ 3,497 ​ ​ ​ Remaining lease terms and discount rates used are as follows; ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 1.72 ​ ​ 2.63 ​ Finance lease assets ​ 0.87 ​ ​ 1.73 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.78 % ​ 7.48 % Finance lease assets ​ ​ 6.54 % ​ 6.43 % ​ Supplemental cash flow information related to leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2023 2022 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows - operating leases ​ $ 1,436 ​ $ 1,016 Operating cash flows - finance leases ​ $ 9 ​ $ 15 Financing cash flows - finance leases ​ $ 96 ​ $ 102 ​ As of June 30, 2023, the maturities of the Company’s future minimum lease payments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2024 ​ $ 1,378 ​ $ 88 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 2,263 ​ ​ 88 Less: Imputed interest ​ ​ (173) ​ ​ (3) Lease liabilities ​ $ 2,090 ​ $ 85 ​ ​

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	7. Goodwill and Other Intangible Assets Goodwill There were no goodwill carrying amounts in the consolidated balance sheets as of June 30, 2023 and 2022. The carrying amount of goodwill by reportable segment and changes during the year ended June 30, 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment Consumer Health Segment Consolidated ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of June 30, 2021 ​ $ 57,165 ​ $ 8,637 ​ $ 65,802 Goodwill impairment ​ (57,165) ​ (8,637) ​ (65,802) Balance as of June 30, 2022 ​ $ — ​ $ — ​ $ — ​ During the year ended June 30, 2022, the Company’s market capitalization significantly declined. The decline was considered a qualitative factor that led management to reassess whether an impairment had occurred. Management’s evaluation indicated that the goodwill related to its reporting units in both the Rx and Consumer Health segments were potentially impaired. The Company then performed a quantitative impairment test by calculating the fair value of the reporting unit and compared that amount to its carrying value. Significant assumptions inherent in the valuation methodologies include, but were not limited to prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in our industry. The decline in market capitalization was an indicator of increased risk thereby increasing the discount rates in the valuation models. The Company determined the fair value of the reporting unit utilizing the discounted cash flow model. Using a risk adjusted weighted-average discount rate, the fair value of the reporting units was less than its carrying value. The Company recognized an impairment charge of $57.2 million in the Rx Segment, associated with the Cerecor and Neos acquisition and a $8.6 million impairment charge in the Consumer Health Segment related to the goodwill associated with the Innovus Acquisition. Other Intangible Assets The tables below provide the summary of the Company’s intangible assets as of June 30, 2023 and June 30, 2022, respectively. Carrying amounts are net of any impairment charges from prior periods. Intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ $ 42,176 ​ $ (10,881) ​ $ — ​ $ 31,295 11.49 Acquired technology right ​ ​ 30,200 ​ ​ (4,054) ​ ​ — ​ ​ 26,146 ​ 14.75 Acquired product distribution rights ​ 9,182 ​ (4,678) ​ (2,975) ​ 1,529 1.00 ​ ​ ​ 81,558 ​ ​ (19,613) ​ ​ (2,975) ​ ​ 58,970 ​ 12.67 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 84,158 ​ $ (19,613) ​ $ (5,575) ​ $ 58,970 12.67 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Net Carrying ​ Remaining ​ Amount Amortization Impairment ​ Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (7,667) ​ ​ (3,224) ​ ​ 34,509 ​ 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (3,581) ​ (2,172) ​ ​ 5,601 ​ 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ 2,600 ​ — ​ ​ — ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 ​ 13.35 ​ The following table summarizes the estimated future amortization expense to be recognized over the next five years and periods thereafter: ​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2024 ​ $ 6,518 2025 ​ ​ 4,989 2026 ​ ​ 4,989 2027 ​ ​ 4,989 2028 ​ ​ 4,989 Thereafter ​ ​ 32,496 Total future amortization expense ​ $ 58,970 ​ Acquired Product Technology Rights The acquired Product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Karbinal® ER. 20-year Poly-Vi-Flor and Tri-Vi-Flor. ADHD Portfolio. Acquired Technology Right TRRP Technology. technology underlines each of Neos’ core products and can potentially be used in future product development initiatives as well. Acquired Product Distribution Rights (and customer list) In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. During the fiscal year ended June 30, 2023, this intangible asset was impaired by $3.0 million due to the discontinuance of products in the Consumer Health Segment. Acquired In-Process R&D IPR&D – NT0502. Other Other intangible assets consist of customer lists, trade names and other technology and licenses. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $6.1 million and $7.8 million during the years ended June 30, 2023 and 2022, respectively. The Company’s strategy is to continue building its portfolio of revenue-generating products by leveraging its commercial team’s expertise to build leading brands within large therapeutic and consumer health markets. As a result of focusing on building the portfolio of revenue-generating products, the Company decided to abandon active development of its NT0502 (N-desethyloxybutynin), a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended June 30, 2023, the Company incurred an impairment charge of $2.6 million related to NT0502 and terminated the licensing agreement. The Company also terminated the license agreement with Cedars-Sinai Medical Center surrounding the Healight technology platform as an additional result of terminating the development of the Healight program. Further, the acquired product distribution rights from Innovus was impaired by $3.0 million due to discontinuance of products in the Consumer Health Segment. During the year ended June 30, 2022, in connection with the decision to discontinue commercializing or divesting certain products within the Rx Segment that have minimal revenue and gross margin contribution, the Company recorded $4.9 million impairment

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Jun. 30, 2023
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	8. Accrued liabilities Accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Accrued savings offers ​ $ 15,739 ​ $ 12,711 Accrued program liabilities ​ ​ 11,012 ​ ​ 9,468 Accrued compensation ​ ​ 5,675 ​ ​ 4,765 Accrued customer and product related fees ​ ​ 6,579 ​ ​ 7,817 Return reserve ​ 5,777 ​ 5,770 Other accrued liabilities ​ ​ 2,017 ​ ​ 3,656 Total accrued liabilities ​ $ 46,799 ​ $ 44,187 ​ The following table details the change in return reserve for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ Return Reserve ​ ​ ​ (In thousands) ​ ​ ​ ​ Balance, June 30, 2021 ​ $ 6,367 Charges to expense ​ ​ 8,568 Payments ​ ​ (9,165) Balance, June 30, 2022 ​ $ 5,770 Charges to expense ​ ​ 8,353 Payments ​ ​ (8,346) Balance, June 30, 2023 ​ $ 5,777 ​ Savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions. Accrued employee compensation includes sales commissions, vacation earned, and accrued payroll. Other accrued liabilities consist of accrued license fees, professional fees, credit card liabilities, taxes payable, legal settlements, and samples expense, none of which individually represent greater than five percent .

Other Liabilities

Other Liabilities	12 Months Ended
	Jun. 30, 2023
Other Liabilities Disclosure [Abstract]
Other Liabilities	9. Other Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangement ​ $ 10,420 ​ $ 13,051 Operating lease liabilities ​ 2,090 ​ 3,317 Contingent value rights ​ ​ — ​ ​ 578 Contingent consideration ​ ​ — ​ ​ 396 Other ​ ​ 1,555 ​ ​ 815 Total other liabilities ​ ​ 14,065 ​ ​ 18,157 Less: current portion ​ ​ (7,090) ​ ​ (5,359) Total other liabilities, noncurrent ​ $ 6,975 ​ $ 12,798 ​ Fixed payment arrangements. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in early satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million each over six quarters beginning September 30, 2021. The Company accounted the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023. The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. As of June 30, 2023, the fixed payment arrangement balance was $1.7 million in other current liabilities and $2.1 million in other non-current liabilities on the consolidated balance sheet. On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $6.0 million to $9.0 million, which reduced our total liability for minimum payments by approximately $8.0 million from the original License Agreement. The settlement payment will be paid in three installments from December 2022 through July 2024. As of June 30, 2023, the balance was $6.6 million. Contingent value rights. 2022 and 2023. As of June 30, 2023, up to $5.0 million of future milestone payments potentially remain. During the years ended June 30, 2023 and 2022, the Company recognized a gain of $0.6 million and $0.8 million, respectively, in the consolidated statements of operations related to the changes in fair values of CVRs. As of June 30, 2023 and 2022, the CVRs balance was zero and $0.6 million, respectively. Contingent consideration . In connection with the Company’s 2020 acquisition of Innovus, the Company recognized approximately $0.2 million in product related contingent consideration. The fair value was based on a discounted value of the future contingent payment using a 30% discount rate based on the estimated risk that the milestones are achieved. Prior to June 30, 2022, the Company’s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR . Prior to June 30, 2022, the royalty payments related to licensing agreements with Magna Pharmaceuticals, Inc. (“Magna”) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company concluded that the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. In 2022, the Company reversed the remaining contingent consideration liabilities of $0.6 million and recorded the $50,000 payment due for termination of the Manga licensing agreements in other current liabilities. The Company recognized a $0.6 million gain from termination of the contingent consideration liability in the consolidated statements of operations for the year ended June 30, 2022. During the year ended June 30, 2023 and 2022, the Company recognized a gain of $0.4 million and a loss of $0.5 million, respectively, from the changes in fair values of contingent considerations. As of June 30, 2023 and 2022, the contingent consideration balance was zero and $0.4 million, respectively. Other.

Line of Credit

Line of Credit	12 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Line of Credit	10. Line of Credit Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the “Revolving Loans”), of which up to $2.5 million was available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans thereunder accrued variable interest through maturity at the one-month Secure Overnight Financing Rate (“SOFR), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022. In connection with the Avenue Capital Agreement, described in Note 12 – Long Term Debt, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the “Eclipse Second Amendment”). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment. The Company incurred $0.1 million in legal and other fees related to the Eclipse Second Amendment, all of which were recorded as deferred financing costs and are being amortized on a straight-line basis over the remaining term of the Eclipse Loan Agreement as interest expense. The unamortized cost of $0.1 million as of June 30, 2022 was included in other noncurrent assets in the consolidated balance sheets. On March 24, 2023, the Company and certain of its subsidiaries entered into an Amendment No. 4 (the Eclipse Amendment”) to the Loan and Security Agreement dated October 2, 2019 (as amended by Amendment No. 1, dated March 19, 2021, Amendment No. 2, dated January 26, 2022, Amendment No. 3, dated June 1, 2022, and the Eclipse Amendment (the “Eclipse Agreement”). The Eclipse Amendment, among other things, provided for an aggregate increase of $2.0 million to the Eclipse Lender’s commitment to make revolving loans from time to time under the Eclipse Agreement and increased the maximum amount available under the revolving credit facility provided under the Eclipse Agreement to $14.5 million. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement with at least five business days prior notice to Eclipse. The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement as amended. The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. Total interest expense on the Revolving Loans, including amortization of deferred financing costs, were $0.7 million and $0.4 million for the years ended June 30, 2023 and 2022. As of June 30, 2023 and 2022, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $1.6 million and $3.8 million, respectively. Unused line of credit amount as of June 30, 2023 was $9.3 million.

Long-term Debt

Long-term Debt	12 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Long-term Debt	11. Long-term Debt Deerfield Debt. The Company evaluated and determined that the fair value of the remaining outstanding debt was $17.4 million as of the March 19, 2021 acquisition date. Accordingly, the Company recorded a premium of $0.8 million, which was the difference between carrying amount and the fair value of the debt and was being amortized into interest expense using the effective interest method over the remaining term of the debt. On January 26, 2022, the Company repaid the remaining principal outstanding in full, plus exit fees and accrued interest under the Deerfield Facility. The Company recognized a gain of $0.2 million during the year ended June 30, 2022 related to the extinguishment of the Deerfield Facility. Total interest expense on the facility, net of premium amortization, was $0.8 million for the period from July 1, 2021 through full repayment on January 26, 2022. Avenue Capital Loan. Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone 1”). The Interest-only Period could further be extended automatically without any action by any party for an additional six months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination. In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement. The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement. On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million. On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants, as described in Note 15 – Stockholders Equity, at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20. On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (“Avenue”) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s August 2022 equity financing. On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 – Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. The interest-only period now extends to the January 26, 2025 maturity date. In addition to the debt discounts discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.59%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $2.7 million and $0.9 million for the years ended June 30, 2023 and 2022. Long-term debt consists of the following; ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2023 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (925) Financing leases, maturing through May 2024 ​ ​ 85 Total debt ​ ​ 14,798 Less: current portion ​ ​ (85) Non-current portion of debt ​ $ 14,713 ​ Future principal payments of long-term debt, including financing leases, are as follows; ​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2024 ​ $ 85 2025 ​ ​ 15,638 Future principal payments ​ ​ 15,723 Less unamortized discount and issuance costs ​ ​ (925) Less current portion ​ ​ (85) Non-current portion of debt ​ $ 14,713 ​

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	12. Fair Value Measurements We determine the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities contingent consideration liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our consolidated balance sheets. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. Recurring Fair Value Measurement The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2023 and 2022, by level within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2023 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ $ 6,403 $ — $ — $ 6,403 Total ​ $ 6,403 $ — $ — ​ $ 6,403 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 396 $ — $ — $ 396 CVR liability ​ ​ 578 ​ — ​ — ​ 578 Derivative warrant liabilities ​ ​ 1,796 ​ ​ — ​ ​ — ​ ​ 1,796 Total ​ $ 2,770 $ — $ — ​ $ 2,770 ​ ​ Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds, and reflect their fair value at Level 1 in the fair value hierarchy. Non-Recurring Fair Value Measurement The Company’s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended June 30, 2023 and 2022, were fixed payment arrangements, goodwill and intangible assets. Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from 10.0% to 15.4%, and are classified as Level 3 inputs in the fair value hierarchy. In May 2022, the Company recognized a fixed payment arrangement liability of $7.6 million relating to the termination of the License, Development, Manufacturing and Supply Agreement with Tris. See Note 9 – Other Liabilities for further information on fixed payment arrangements. ​ Based on the Company’s impairment analyses for fiscal years 2023 and 2022, the Company recorded an impairment charge of $5.6 million on intangible assets during the year ended June 30, 2023; and an impairment charge of $7.1 million on intangible assets and $65.8 million on goodwill for the year ended June 30, 2022. Valuation of goodwill and intangible assets involves significant Level 3 inputs in estimating their fair values. These input assumptions included revenue growth rates, forecasted EBITDA margins, and the selection of a discount rate. These assumptions may be affected by expectations about future market or economic conditions. See Note 7 - Goodwill and Other Intangible Assets and Note 2 - Summary of Significant Accounting Policies, for further discussion on the fair value measurement of goodwill and other intangible assets. ​ Summary of Level 3 Input Changes The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the year ended June 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent ​ ​ Warrant ​ ​ Liability ​ Consideration ​ ​ Liability ​ ​ (In thousands) Balance as of June 30, 2022 $ 578 ​ $ 396 ​ $ 1,796 Included in earnings ​ (578) ​ ​ (391) ​ ​ (6,391) Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ Issues — ​ — ​ 10,998 Settlements — ​ (5) ​ — Balance as of June 30, 2023 $ — ​ $ — ​ $ 6,403 ​ Level 3 Inputs Changes in the fair value of contingent liabilities in subsequent periods are recorded as a gain or loss in the consolidated statements of operations. Significant assumptions used in valuing the CVRs were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2023 ​ 2022 Leveraged Beta 0.84 ​ 0.85 ​ Market risk premium ​ 6.35 % ​ 6.22 % Risk-free interest rate ​ 5.47 % ​ 2.86 % Discount ​ 22.00 % ​ 20.50 % Company specific discount 10.00 % 10.00 % ​ Significant assumptions used in valuing the derivative warrant liabilities at issuance date were as follows: ​ ​ ​ ​ ​ ​ ​ August 9, ​ 2022 Expected volatility 89.89 % Equivalent term (years) ​ 4.11 ​ Risk-free rate ​ 3.09 % Dividend yield ​ 0.00 % ​ ​ ​ ​ ​ ​ ​ ​ June 8, ​ 2023 Expected volatility 83.26 % Equivalent term (years) ​ 5.01 ​ Risk-free rate ​ 3.87 % Dividend yield ​ 0.00 % ​ Significant assumptions used in valuing ​ ​ ​ ​ ​ ​ June 30, ​ 2023 Expected volatility 83.42 % Equivalent term (years) ​ 3.59-4.95 ​ Risk-free rate ​ 4.13-4.40 % Dividend yield ​ 0.00 % ​ ​ ​ ​ ​ Expected volatility was based primarily on historical volatility. The Company chose to use a two-year lookback on historical volatility to avoid the effects of COVID-19 and the Innovus acquisition. The Company believes this method produced an estimate that was representative of the Company’s expectations of future volatility over the expected term of these warrants, and will not differ materially. If expected volatility by the active market is higher than estimated, the derivative may result in a greater fair value. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants. ​

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes For the fiscal year of 2023, there was no income tax benefit, primarily driven by Section 382 limitation on post-TCJA (“Tax Cuts and Jobs Act”) net operating loss (“NOL”) utilization, further described below. As of June 30, 2023, the Company had $0.1 million deferred tax asset (DTA) included in other non-current assets, $0.1 million deferred tax liability (DTL) included in other long-term liabilities, and $0.1 million income tax payable in accrued liabilities in the consolidated balance sheet. Section 382 Limitation Under the provisions of the Internal Revenue Code, substantial changes in the Company’s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. As part of the Company’s Section 382 analysis, an ownership change was determined to have occurred in March 2022 at a point in time when the Company had a net unrealized built-in gain. As such, the NOL generated during that period has been allocated and the post-change NOL (approximately $12 million) is determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation. The Company also determined that ownership change occurred in June 2023 at a time that the Company was in a net unrealized loss position. As a result of the Section 382 analysis, the Company had estimated $0.3 million of disallowed recognized built-in loss and had carried forward as an operating loss as of June 30, 2023. The Company had federal net operating losses of approximately $504.0 million as of June 30, 2023, that subject to limitation (as described above), may be available in future tax years to offset taxable income. Of the available federal net operating losses, approximately $172.0 million can be carried forward indefinitely, while the remaining balance will begin to expire in 2024 and completely expire in 2027. As of June 30, 2023, the Company had research and development credits of $3.0 million, which begin to expire in 2024. The available state net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2039. As of June 30, 2023, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards. The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized. Generally, it is not appropriate to use zero as an applicable tax rate and rather, a deferred tax asset should be recorded at the applicable tax rate and a valuation of an equal amount would be provided. However, under certain circumstances it may be appropriate to follow an alternative approach and use a zero rate to write off the asset against the valuation allowance, reducing the valuation allowance and gross deferred tax assets disclosed. The Company considered both accounting viewpoints and determined it would present its NOL carryforwards gross with a full valuation allowance and not apply a zero rate to NOL carryforwards expected to expire unutilized. In review of the Company’s consolidated deferred position excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and not utilized against a net DTL. The provision for income taxes consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Current: ​ ​ ​ ​ ​ ​ Federal ​ $ 80 ​ $ — State ​ 46 ​ 7 Total current tax expense ​ 126 ​ 7 Deferred: ​ ​ ​ ​ Federal ​ (109) ​ (91) State ​ (17) ​ (26) Total deferred tax expense ​ (126) ​ (117) Provision for income taxes ​ $ — ​ $ (110) ​ Income tax benefit resulting from applying statutory rates in jurisdictions in which the Company is taxed (Federal and various states) differs from the income tax provision (benefit) in the financial statements. Reconciliation of the U.S. federal statutory income tax rates to our effective tax rate is as follows. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2023 ​ ​ 2022 ​ ​ (In thousands) Tax at statutory rate ​ $ (3,581) ​ (22.30) % ​ $ (23,159) ​ (21.00) % State income taxes, net of federal benefit ​ ​ 16 ​ 0.10 % ​ ​ 601 ​ 0.55 % Permanent difference ​ ​ — ​ — % ​ ​ — ​ — % Stock based compensation ​ ​ — ​ — % ​ ​ 273 ​ 0.27 % Contingent consideration ​ ​ (193) ​ (1.20) % ​ ​ (155) ​ (0.14) % 162(m) limitation ​ ​ — ​ — % ​ ​ 76 ​ 0.08 % Goodwill impairment ​ ​ — ​ — % ​ ​ 9,733 ​ 8.83 % Transaction costs ​ ​ — ​ — % ​ ​ — ​ — % Change in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Remeasurement of deferred taxes ​ ​ — ​ — % ​ ​ — ​ — % Effect of phased-in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Loss on debt extinguishment and interest expense ​ ​ — ​ — % ​ ​ — ​ — % Change in valuation allowance ​ ​ 3,641 ​ 22.68 % ​ ​ 12,472 ​ 11.31 % Derivative income ​ ​ — ​ — % ​ ​ — ​ — % Other ​ ​ 117 ​ 0.72 % ​ ​ 49 ​ 0.01 % Net income tax provision (benefit) ​ $ — ​ 0.00 % ​ $ (110) ​ (0.09) % ​ Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Deferred tax assets: ​ ​ ​ ​ ​ ​ Net operating loss carry forward ​ $ 114,265 ​ $ 114,443 Accrued Rebates ​ ​ 6,994 ​ ​ 5,944 Share-based compensation ​ 4,250 ​ 2,773 Accrued expenses ​ ​ 758 ​ ​ 817 R&D credits ​ 2,416 ​ 2,423 Interest ​ ​ 4,188 ​ ​ 2,975 Warrant Derivatives ​ ​ 1,504 ​ ​ — Section 174 Capitalization ​ ​ 836 ​ ​ — Inventory ​ 743 ​ 1,177 Lease liability ​ 492 ​ 799 Other ​ ​ 1,332 ​ ​ 1,301 Total deferred tax assets ​ ​ 137,778 ​ ​ 132,652 Less: valuation allowance ​ ​ (136,400) ​ ​ (128,966) Deferred tax assets, net of valuation allowance ​ ​ 1,378 ​ ​ 3,686 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Intangibles ​ (845) ​ (2,717) Fixed Assets ​ (50) ​ (308) ROU asset ​ ​ (483) ​ ​ (788) Total deferred tax liabilities ​ ​ (1,378) ​ ​ (3,813) Net deferred tax liabilities ​ $ — ​ $ (127) ​ In fiscal year 2022, the impairment of goodwill decreased net deferred tax liabilities by $0.1 million resulting in an income tax benefit of $0.1 million. As of June 30, 2022, the Company had $0.1 million deferred tax liabilities included in other long-term liabilities in the consolidated balance sheet. The Company had federal net operating losses of approximately $503.2 million as of June 30, 2022, subject to Section 382 limitation. The Company has recorded a valuation allowance of $136.4 million and $129.0 million at June 30, 2023 and 2022, respectively, to reserve its net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not, that it will realize the benefits of these deductible differences, net of the valuation allowance provided. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has no accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company’s net operating loss carryforward, interest expense carryover or research and development credit carryover and therefore do not require recognition. As a result of these timing differences, at June 30, 2023 and 2022, the Company had gross unrecognized tax benefits related to uncertain tax positions of $2.9 million and $2.8 million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense. A tabular roll-forward of the Company’s gross unrecognized tax benefits is below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Beginning balance ​ $ 2,822 ​ $ 3,435 Increase resulting from prior period tax positions ​ — ​ — Increase resulting from current period tax positions ​ ​ 246 ​ 34 Decrease resulting from current period tax positions ​ (120) ​ ​ (647) Ending balance ​ $ 2,948 ​ $ 2,822 ​ The change in the Company’s gross unrecognized tax benefits relates to the acquisition of Neos, whereby historic tax positions of Neos were inherited in the acquisition. Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to 2004 being subject to examination.

Stockholders Equity

Stockholders Equity	12 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders Equity	14. Stockholders’ Equity The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share. As of June 30, 2023 and 2022, the Company had 5,517,174 and 1,928,941 common shares issued and outstanding, respectively, and no preferred shares issued and outstanding. Included in the common stock outstanding are 40,996 shares of unvested restricted stock issued to executives, directors, and employees. On June 8, 2020, the Company filed a shelf registration statement (the “2020 Shelf”), which was declared effective by the SEC on June 17, 2020, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. On June 4, 2021, the Company entered into an agreement with an agent for the sale of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the year ended June 30, 2023, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total gross proceeds of approximately $3.0 million before deducting underwriting discounts, commissions, and other offering expenses of $0.1 million. The 2020 Shelf expired in June 2023. On September 28, 2021, the Company filed a shelf registration statement (the “2021 Shelf”), which was declared effective by the SEC on October 7, 2021, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. As of June 30, 2023, approximately $82.4 million remain available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3. The 2021 Shelf expires in October 2024. On March 7, 2022, the Company closed on an underwritten public offering utilizing the 2021 Shelf, pursuant to which, the Company sold, (i) 151,500 shares of the Company’s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common stock purchase warrants to purchase up to 333,300 shares of common stock (the “March 2022 Offering”). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $26.00 per share of common stock and are exercisable six months On August 11, 2022, the Company closed on an underwritten public offering (the “August 2022 Offering”) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.001 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance, and are classified as derivative warrant liabilities with the offset in additional paid in capital in stockholders’ equity in the Company’s consolidated financial statements (See Note 16 – Warrants). ​ On June 8, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue and sell an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the “Pre-Funded Warrants”), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the “Common Warrants”). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the “Exchange Warrants”). Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (See Note 16 – Warrants). ​

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	15. Equity Incentive Plans 2023 Equity Incentive Plan. On May 18, 2023, the Company’s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”). Prior to the Company’s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (“Aytu 2015 Plan”) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (“the Neos 2015 Plan”) (collectively the “2015 Plans”). For the 2023 Equity Incentive Plan, the stockholders approved (a) awards Aytu 2015 Plan. equity awards. On February 13, 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years. Neos 2015 Plan. Stock Options During the fiscal year ended June 30, 2023, 49,212 stock options were granted. The weighted-average grant date fair value of options granted during the year ended June 30, 2023 was $4.00. As of June 30, 2023, there was $0.1 million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.2 years. No options were granted during the fiscal year 2022. Stock option activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 3,899 ​ $ 209.70 7.77 Granted 49,212 ​ ​ 4.00 Forfeited/Cancelled (172) ​ ​ 128.99 Expired (177) ​ ​ 131.39 Outstanding at June 30, 2023 52,762 ​ $ 18.37 9.06 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at June 30, 2023 3,022 ​ $ 225.74 6.17 ​ The following table details the options outstanding at June 30, 2023 by range of exercise prices: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Contractual ​ ​ ​ ​ ​ Range of ​ Number of ​ Average ​ Life of ​ Number of ​ Weighted Exercise ​ Options ​ Exercise ​ Options ​ Options ​ Average Prices ​ Outstanding ​ Price ​ Outstanding ​ Exercisable ​ Exercise Price $ 4.00 49,212 ​ $ 4.00 9.26 — ​ $ — $ 123.16 - 290.00 3,550 ​ $ 217.52 6.26 3,022 ​ $ 225.74 ​ ​ 52,762 ​ $ 18.37 9.06 3,022 ​ $ 225.74 ​ Restricted Stock During the year ended June 30, 2023, as a result of the change in members of the Company’s board, the Company accelerated unvested shares for two former members and recorded $1.5 million of non-cash equity compensation expense. On December 19, 2022, the Company entered into a Stipulation of Compromise and Settlement (the “Stipulation”). As a part of the terms of the Stipulation, the Company agreed to rescind 25% of the aggregate 2021 grants to board members. As a result of the recission of the shares, the Company recorded $0.6 million in non-cash compensation during the year ended June 30, 2023. During the year ended June 30, 2023, the Company granted a total of 6,825 shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu 2015 Plan, of which 1/3 1/12 on the first each quarter thereafter subject Restricted stock activity under the Aytu 2015 Plan is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 80,373 ​ $ 148.91 Granted 6,825 ​ ​ 3.79 Vested (42,434) ​ ​ 126.98 Forfeited/Cancelled ​ (6,689) ​ ​ 135.66 Unvested at June 30, 2023 38,075 ​ $ 142.20 ​ As of June 30, 2023, there was $3.6 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.0 years. The total fair value of restricted stock vested during the year ended June 30, 2023 was $0.2 million. The Company previously issued 4 shares of restricted stock outside of the Aytu 2015 Plan, which vest in July 2026. On January 17, 2022, the Company granted 5,000 shares of restricted stock to a member of its management team outside of the Aytu 2015 Plan, of which 1/3 1/12 each quarter thereafter subject to continuing employment Restricted Stock Units For the year ended June 30, 2023, the Company did not grant restricted stock units (“RSU”). RSU activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 8,500 ​ $ 25.88 Vested (3,537) ​ ​ 26.26 Unvested at June 30, 2023 4,963 ​ $ 25.62 ​ As of June 30, 2023, there was $0.1 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.6 years. The total fair value of RSUs vested during the year ended June 30, 2023 was immaterial. Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2023 2022 ​ ​ (In thousands) Cost of sales ​ $ 28 ​ $ 31 Research and development ​ ​ 30 ​ ​ 536 Selling and marketing ​ ​ 23 ​ ​ 24 General and Administrative ​ 5,965 ​ 4,657 Total stock-based compensation expense ​ $ 6,046 ​ $ 5,248

Warrants

Warrants	12 Months Ended
	Jun. 30, 2023
Warrants and Rights Note Disclosure [Abstract]
Warrants	16. Warrants Liability Classified Warrants The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation valuation model, and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations. On June 8, 2023, the Company entered into a securities purchase agreement (the “Security Purchase Agreement”) pursuant to which the Company agreed to issue and sell an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the “Pre-Funded Warrants”), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the “Common Warrants”). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the “Exchange Warrants”). Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Security Purchase Agreement) of $12 million (see Note 14 – Stockholders’ Equity). On August 11, 2022, the Company closed on the August 2022 Offering, pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32 and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 – Stockholders’ Equity). In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the associated common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a 20 On March 7, 2022, the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) 151,500 shares of the Company’s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common warrants to purchase up to 333,300 shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $26.00 per share of common stock and are exercisable six months On January 26, 2022, as consideration for entering into the Avenue Capital Agreement as described in Note 11 – Long-term Debt, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the issuance (see Note 11 – Long-term Debt for further details). Outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see Note 12 – Fair Value Considerations). A summary of warrants is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 434,328 ​ $ 92.60 4.8 Warrants issued 6,028,331 ​ 1.61 5.0 Warrants exercised ​ (87,500) ​ ​ 0.02 ​ 5.0 Warrant adjusted ​ 181,461 ​ ​ 5.04 ​ 3.9 Warrants expired (18,568) ​ 2,011.56 — Outstanding June 30, 2023 6,538,052 ​ $ 4.42 4.71 ​

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jun. 30, 2023
Retirement Benefits [Abstract]
Employee Benefit Plan	17. Employee Benefit Plan Subsequent to the merger with Neos, Aytu had two 401(k) plans the (“Neos Plan”) and the (“Aytu Plan’) both plans allow participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Neos Plan matched 100% of the first 3% contributed by employees and matched 50% on the next 4% and 5% contributed by the employees. The Company’s match for the Neos Plan was approximately $0.4 million for the year ended June 30, 2022. The Aytu Plan matched 50% of the first 6% contributed to the plan by employees. The Company’s match for the Aytu Plan was approximately $0.2 million for both years ended June 30, 2023 and 2022. In July 2022, the Company transferred the Neos Plan into the Aytu BioPharma Employee Retirement Plan and in February 2023 the Company transferred the Aytu Plan into the Aytu BioPharma Employee Retirement Plan. The Aytu BioPharma Employee Retirement Plan matches 100% of the first 3% contributed by employees and matches 50% of the next 4% and 5% contributed by the employees. The Company’s match for the Aytu BioPharma Employee Retirement Plan was approximately $0.7 million during the year ended June 30, 2023.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	18. Commitments and Contingencies Pediatric Portfolio Fixed Payments and Product Milestone The Company assumed two fixed, periodic payment obligations to an investor (the “Fixed Obligation”). Under the first fixed obligation, the Company was to pay monthly payment of $0.1 million beginning November 1, 2019 through January 2021, with a balloon payment of $15.0 million that was to be due in January 2021 (“Balloon Payment Obligation”). A second fixed obligation requires the Company pay a minimum of $0.1 million monthly through February 2026, except for $0.2 million paid in January 2020. On May 29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the “Early Payment Agreement”) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the second fixed obligation. The company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million over the next six quarters commencing September 30, 2021. The Company accounted for the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023. The Company acquired a Supply and Distribution Agreement with Tris (the “Tris Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Tris Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. Prior to June 30, 2022, the Company’s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR . Product Contingent Liability In February 2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the Merger, Innovus is obligated to make five additional payments of $0.5 million when certain levels of FlutiCare sales are achieved. In fiscal year 2023, the manufacturer associated with this contingent liability filed for bankruptcy. There were no payments required in fiscal 2023. Rumpus Earn Out Payments On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company assumed the responsibility for paying annual maintenance fees of $25,000, a license option fee of $0.6 million payable in April 2022, and upon the achievement of certain regulatory and commercial milestones, up to $101.7 million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for paying minimum annual royalties escalating from $5,000 to $20,000 beginning in calendar year 2022, royalties of 3.0% of net product sales, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. During the year ended June 30, 2022, AR101 received Orphan Drug Designation (“ODD”) and Fast Track designation from the FDA, resulting in total milestone payments of $4.0 million, which were paid in 109,447 shares of common stock and $2.6 million in cash. Operating Lease In May 2023, the Company entered into an operating lease agreement to relocate its principal office within Denver, Colorado. The lease has a commencement date of October 1, 2023 with an initial term of five and a half years Variable lease payments will be expensed as incurred. Under the lease agreement, the Company has one five-year renewal option through March 2034. Legal Matters Witmer Class-Action Securities Litigation. ​ Sabby Litigation. ​ Stein Litigation. ​

License Agreements

License Agreements	12 Months Ended
	Jun. 30, 2023
License Agreement [Abstract]
License Agreements	19. License Agreements Healight In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, ten years after the first bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency. Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and approximately $0.1 million in earlier patent prosecution fees. As a result of the Company’s focus on the revenue growth of its commercial business, the Company had terminated the licensing agreement with Cedars-Sinai Medical Center, effective May 9, 2023. NeuRx In October 2018, Neos entered into an Exclusive License Agreement (“NeuRx License”) with NeuRx Pharmaceuticals LLC (“NeuRx”), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx’s proprietary compound designated as NRX-101, referred to by Neos as NT0502. NT0502 is a new chemical entity that is being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i) the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii) expiration of regulatory exclusivity of such licensed product in such country. In April 2023, the Company returned the NT0502 rights to NeuRx in exchange for, and to receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on NT0502. Teva On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. Actavis On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. Shire In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the “2014 License Agreement”) with Shire LLC (“Shire”) for a non-exclusive license to certain patents for certain activities with respect to Neos’ New Drug Application (the “NDA”) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid a lump sum, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. The settlement agreement expires May of 2023. In March 2017, Neos entered into a License Agreement (the “2017 License Agreement”) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos’ NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos is paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021. The royalties are recorded as cost of sales in the same period as the net sales upon which they are calculated. Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents.

Segment Information

Segment Information	12 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Information	20. Segment Information The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contains the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment. During the year ended June 30, 2023, the Rx Segment recognized an impairment loss of $2.6 million due to ceasing active development of the NT0502 product candidate as a result of the Company’s increased focus on commercial efforts. The Consumer Health Segment recognized an impairment loss of $3.0 million from intangible assets (see Note 7 — Goodwill and Other Intangible Assets) and an inventory write-off of During the year ended June 30, 2022, the Rx Segment recognized a total impairment loss of $64.6 million related to impairment of goodwill and write-down of assets due to the discontinuance of five non-core products, the Consumer Health Segment recognized $10.8 million of goodwill and intangible assets write downs (see Note 7 — Goodwill and Other Intangible Assets). Select financial information for these segments is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ Rx ​ ​ Consumer Health ​ ​ Consolidated ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue, net $ 73,799 ​ $ 33,600 ​ $ 107,399 Loss from operations $ (7,358) ​ $ (9,707) ​ $ (17,065) ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization $ 6,271 ​ $ 1,116 ​ $ 7,387 Impairment and write-off expense $ 2,730 ​ $ 5,094 ​ $ 7,824 Stock based compensation $ 5,722 ​ $ 324 ​ $ 6,046 ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue, net $ 61,121 ​ $ 35,548 ​ $ 96,669 Loss from operations $ (92,441) ​ $ (17,465) ​ $ (109,906) ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization $ 7,821 ​ $ 1,557 ​ $ 9,378 Impairment expense $ 64,649 ​ $ 10,809 ​ $ 75,458 Stock based compensation $ 5,190 ​ $ 58 ​ $ 5,248 ​

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events Distribution and Supply Agreement In July 2023, the Company entered into an exclusive collaboration, distribution and supply agreement with a privately-owned pharmaceutical company for Adzenys XR-ODT and Cotempla XR-ODT product lines. The pharmaceutical company will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT; and will focus on distributing and selling these products for patients in Israel and the Palestinian Authority. The Company will commit to product supply based on forecasts and provide product training. Due to the nascency of the collaboration, estimates of its financial effect cannot be made. This agreement represents the Company’s first international commercial agreement for Adzenys and Cotempla.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Principals of Consolidation	Principals of Consolidation .
Basis of Presentation	Basis of Presentation .
Prior Period Reclassification and Previously Reported Financial Statements	Prior Period Reclassification . Previously Reported Financial Statements . SEC Staff Accounting Bulletin No. 99, “Materiality,” and the Financial Accounting Standards Board (“FASB”), Statement of Financial Accounting Concepts No. 2 “Qualitative Characteristics of Accounting Information” indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the consolidated financial statements as of and for the fiscal year ended June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to this period for comparative purposes. The adjustments did not change the Company’s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations. The consolidated financial statements as of and for the fiscal year ended June 30, 2022 have been adjusted as shown in the following tables. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Balance Sheet data ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ $ - ​ $ 1,796 ​ $ 1,796 Total liabilities ​ $ 91,531 ​ $ 1,784 ​ $ 93,315 Additional paid-in capital ​ $ 334,560 ​ $ (3,174) ​ $ 331,386 Accumulated deficit ​ $ (288,472) ​ $ 1,394 ​ $ (287,078) Total stockholders’ equity ​ $ 46,092 ​ $ (1,784) ​ $ 44,308 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Twelve Months Ended ​ ​ June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liability ​ $ 211 ​ $ 1,394 ​ $ 1,605 Total other income, net (1) ​ $ 1,278 ​ $ (261) ​ $ 1,017 Loss before income tax ​ $ (110,283) ​ $ 1,394 ​ $ (108,889) Net loss ​ $ (110,173) ​ $ 1,394 ​ $ (108,779) Basic and diluted net loss per common share ​ $ (75.00) ​ $ 0.99 ​ $ (74.01) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Issuance of common stock, net of issuance cost ​ $ 11,652 ​ $ (2,798) ​ $ 8,854 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flow data ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (110,173) ​ $ 1,394 ​ $ (108,779) Gain on derivative warrant liability ​ $ (211) ​ $ (1,394) ​ $ (1,605) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1) Includes reclassification of gain or loss from the fair value of contingent consideration. See Prior Period Reclassification in Note 2 – Summary of Significant Accounting Policies. Previously Reported Segment Information .
Cash and Cash Equivalents	Cash and Cash Equivalents .
Accounts Receivable, net	Accounts Receivable, net . million for both years ended June 30, 2023 and 2022. The table below presents the opening and closing balances of receivables from customers. ​ ​ ​ ​ ​ ​ ​ ​ Accounts Receivable, gross ​ ​ ​ (in thousands) Opening balance, June 30, 2022 ​ $ 24,219 Closing balance, June 30, 2023 ​ ​ 31,927 Increase ​ $ 7,708 ​ ​ ​ ​ Opening balance, June 30, 2021 ​ $ 30,325 Closing balance, June 30, 2022 ​ ​ 24,219 Decrease ​ $ (6,106) ​ ​ ​ ​ ​ The table below details the change in allowance for discount, and allowance for chargeback for the periods presented. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for Discount ​ ​ Allowance for Chargeback ​ ​ Total Allowance ​ ​ ​ (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance, June 30, 2021 ​ $ 1,133 ​ $ 1,016 ​ $ 2,149 Charges to expense ​ ​ 6,760 ​ ​ 4,598 ​ ​ 11,358 Payments ​ ​ (6,592) ​ ​ (4,408) ​ ​ (11,000) Balance, June 30, 2022 ​ $ 1,301 ​ $ 1,206 ​ $ 2,507 Charges to expense ​ ​ 9,074 ​ ​ 4,554 ​ ​ 13,628 Payments ​ ​ (8,597) ​ ​ (4,548) ​ ​ (13,145) Balance, June 30, 2023 ​ $ 1,778 ​ $ 1,212 ​ $ 2,990
Inventories	Inventories . The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified.
Going Concern Determination	Going Concern Determination .
Property and equipment, net	Property and equipment, net . Furniture equipment two shorter of the estimated useful life
Leases	Leases . Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company’s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company’s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less. Operating leases are included in other liabilities in the Company’s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company’s consolidated balance sheets. Income from subleasing is recognized on a straight-line basis over the sublease term, subject to collectability issues which will limit the income recognized to payment received until collectability is no longer an issue. Any variable payments are recognized as incurred.
Acquisitions and Business Combination and Contingent considerations	Acquisitions . Contingent consideration . . Business Combination and Contingent considerations . The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.
Warrants	Warrants.
Revenue Recognition	Revenue Recognition . Segment”). The Company evaluates its contracts with customers to determine revenue recognition using the following five-step model: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) a performance obligation is satisfied. There is not a recognized financing component related to product sales. Rx Segment Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally “free-on-board” destination when shipped domestically within the United States and “free-on-board” shipping point when shipped internationally consistent with the contractual terms. Rx product revenue is recognized net of consideration paid to the Company’s customers and other adjustments to the transaction price (known as “Gross to Net” adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions. The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as “Gross to Net” adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. The Gross to Net adjustments include: ● Savings offers The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. ● Prompt payment discounts Prompt payment discounts are based on standard provisions of wholesalers’ services. ● Wholesale distribution fees Wholesale distribution fees are based on definitive contractual agreements for the management of the Company’s products by wholesalers. ● Rebates The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. ● Wholesaler chargebacks The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers’ end customers. ● Returns Wholesalers’ contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate. Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company’s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do not believe variances between actual and estimated amounts have been material. Consumer Health Segment The Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) is from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales.
Customer Contract Costs	Customer Contract Costs .
Concentration of Credit Risk	Concentration of Credit Risk . The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions. The Company is also subject to credit risk from accounts receivable related to product sales. The Company’s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company’s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company’s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally forty The following table presents customers that contributed more than 10% of gross revenue and accounts receivable : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of gross revenue ​ Percentage of accounts receivable ​ ​ June 30, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 Customer A ​ 43 % ​ 41 % ​ 50 % ​ 52 % Customer B ​ 18 % ​ 20 % ​ 19 % ​ 25 % Customer C ​ 17 % ​ 18 % ​ 14 % ​ 18 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Costs of Sales	Costs of Sales .
Stock-Based Compensation	Stock-Based Compensation . Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company’s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the “simplified method,” which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn’t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur.
Research and Development	Research and Development
Intangible Assets	Intangible Assets .
Impairment of Long-lived Assets and Goodwill	Impairment of Long-lived Assets and Goodwill . Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company’s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company’s outlook and market performance of the Company’s industry forecasted financial performance indicate that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company’s industry.
Advertising Costs	Advertising Costs .
Income Taxes	Income Taxes . balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations.
Debt issuance costs, discounts (premium)	Debt issuance costs, discounts (premiums) .
Segment information	Segment information .
Paragraph IV litigation costs	Paragraph IV litigation costs .
Net Loss Per Common Share	Net Loss Per Common Share . The following table sets-forth securities excluded from the calculation of diluted earnings per share. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2023 2022 Warrant to purchase common stock (Note 16) ​ 6,538,052 434,328 Employee stock options (Note 15) ​ 52,762 3,899 Employee unvested restricted stock (Note 15) ​ 40,996 85,377 Employee unvested restricted stock units ​ (Note 15) ​ 4,963 ​ 8,500 Total ​ ​ ​ 6,636,773 532,104
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements Reference Rate Reform. Reference Rate Reform (Topic 848) “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” Earnings Per Share. “Earnings Per Share (Topic260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options”. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” Financial Instruments – Credit Losses upon adoption of the new credit losses standard. The effective dates and transition for ASU 2019-05 aligns with those of ASU 2016-13. In March 2022, the FASB issued ASU 2022-02, “ Financial Instruments – Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of the impact of the immaterial correction of an error	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Balance Sheet data ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ $ - ​ $ 1,796 ​ $ 1,796 Total liabilities ​ $ 91,531 ​ $ 1,784 ​ $ 93,315 Additional paid-in capital ​ $ 334,560 ​ $ (3,174) ​ $ 331,386 Accumulated deficit ​ $ (288,472) ​ $ 1,394 ​ $ (287,078) Total stockholders’ equity ​ $ 46,092 ​ $ (1,784) ​ $ 44,308 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Twelve Months Ended ​ ​ June 30, 2022 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ ​ Reported ​ Adjustment ​ As Adjusted ​ ​ (in thousands) Statement of Operation data ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on derivative warrant liability ​ $ 211 ​ $ 1,394 ​ $ 1,605 Total other income, net (1) ​ $ 1,278 ​ $ (261) ​ $ 1,017 Loss before income tax ​ $ (110,283) ​ $ 1,394 ​ $ (108,889) Net loss ​ $ (110,173) ​ $ 1,394 ​ $ (108,779) Basic and diluted net loss per common share ​ $ (75.00) ​ $ 0.99 ​ $ (74.01) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Stockholders' Equity data ​ ​ ​ ​ ​ ​ ​ ​ ​ Issuance of common stock, net of issuance cost ​ $ 11,652 ​ $ (2,798) ​ $ 8,854 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flow data ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (110,173) ​ $ 1,394 ​ $ (108,779) Gain on derivative warrant liability ​ $ (211) ​ $ (1,394) ​ $ (1,605) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1) Includes reclassification of gain or loss from the fair value of contingent consideration. See Prior Period Reclassification in Note 2 – Summary of Significant Accounting Policies.
Schedule of receivables from customers	​ ​ ​ ​ ​ ​ ​ ​ Accounts Receivable, gross ​ ​ ​ (in thousands) Opening balance, June 30, 2022 ​ $ 24,219 Closing balance, June 30, 2023 ​ ​ 31,927 Increase ​ $ 7,708 ​ ​ ​ ​ Opening balance, June 30, 2021 ​ $ 30,325 Closing balance, June 30, 2022 ​ ​ 24,219 Decrease ​ $ (6,106) ​ ​ ​ ​
Schedule of allowance for discounts and allowance for chargebacks	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for Discount ​ ​ Allowance for Chargeback ​ ​ Total Allowance ​ ​ ​ (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance, June 30, 2021 ​ $ 1,133 ​ $ 1,016 ​ $ 2,149 Charges to expense ​ ​ 6,760 ​ ​ 4,598 ​ ​ 11,358 Payments ​ ​ (6,592) ​ ​ (4,408) ​ ​ (11,000) Balance, June 30, 2022 ​ $ 1,301 ​ $ 1,206 ​ $ 2,507 Charges to expense ​ ​ 9,074 ​ ​ 4,554 ​ ​ 13,628 Payments ​ ​ (8,597) ​ ​ (4,548) ​ ​ (13,145) Balance, June 30, 2023 ​ $ 1,778 ​ $ 1,212 ​ $ 2,990
Schedule of concentration of business risk	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of gross revenue ​ Percentage of accounts receivable ​ ​ June 30, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 Customer A ​ 43 % ​ 41 % ​ 50 % ​ 52 % Customer B ​ 18 % ​ 20 % ​ 19 % ​ 25 % Customer C ​ 17 % ​ 18 % ​ 14 % ​ 18 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Antidilutive securities excluded from the computation of earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2023 2022 Warrant to purchase common stock (Note 16) ​ 6,538,052 434,328 Employee stock options (Note 15) ​ 52,762 3,899 Employee unvested restricted stock (Note 15) ​ 40,996 85,377 Employee unvested restricted stock units ​ (Note 15) ​ 4,963 ​ 8,500 Total ​ ​ ​ 6,636,773 532,104

Revenues from Contracts with _2

Revenues from Contracts with Customers (Tables)	12 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2023 2022 ​ ​ (In thousands) Rx Segment $ 73,799 $ 61,121 Consumer Health Segment ​ ​ 33,600 ​ ​ 35,548 Consolidated revenue $ 107,399 $ 96,669
Schedule of revenue by product lines	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2023 2022 Rx Segment ​ (In thousands) ADHD ​ $ 46,855 ​ $ 42,855 Pediatric ​ ​ 25,377 ​ ​ 16,084 Other ​ ​ 1,567 ​ ​ 2,182 ​ ​ $ 73,799 ​ $ 61,121
Schedule of product revenues by geographic location	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2023 2022 ​ ​ (In thousands) U.S. ​ $ 106,918 ​ $ 94,606 International ​ 481 ​ 2,063 Total net revenue ​ $ 107,399 ​ $ 96,669 ​

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ (In thousands) Raw materials $ 1,301 $ 1,814 Work in process ​ ​ 2,956 ​ ​ 1,838 Finished goods ​ 7,738 ​ 7,197 Inventories ​ $ 11,995 ​ $ 10,849 ​

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,433 $ 2,487 Leasehold improvements 999 ​ 999 Office equipment, furniture and other 1,125 ​ 1,128 Lab equipment 832 ​ 832 Assets under construction 107 ​ — Property and equipment, gross ​ ​ 5,496 ​ ​ 5,446 Less accumulated depreciation and amortization ​ ​ (3,681) ​ ​ (2,421) Property and equipment, net $ 1,815 ​ $ 3,025 ​

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of components of lease expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ ​ ​ June 30, ​ ​ ​ 2023 2022 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 1,402 ​ $ 1,299 Operating expenses Short-term lease cost ​ 97 ​ 152 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets ​ 66 ​ 73 Cost of sales Interest on lease liabilities ​ ​ 9 ​ ​ 14 ​ Other (expense), net Total net lease cost ​ $ 1,574 ​ $ 1,538
Schedule of balance sheet information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, Balance Sheet Classification ​ ​ 2023 ​ 2022 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 2,054 ​ $ 3,271 Operating lease right-of-use asset Finance lease assets ​ ​ 159 ​ 256 Property and equipment, net Total leased assets ​ $ 2,213 ​ $ 3,527 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,258 ​ $ 1,227 ​ Other current liabilities Finance leases ​ ​ 85 ​ ​ 96 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 832 ​ ​ 2,090 ​ Other liabilities Finance leases ​ ​ — ​ ​ 84 ​ Debt, net of current portion Total lease liabilities ​ $ 2,175 ​ $ 3,497 ​ ​
Schedule of remaining lease term and discount rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 1.72 ​ ​ 2.63 ​ Finance lease assets ​ 0.87 ​ ​ 1.73 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.78 % ​ 7.48 % Finance lease assets ​ ​ 6.54 % ​ 6.43 %
Schedule of supplemental cash flow information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ 2023 2022 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows - operating leases ​ $ 1,436 ​ $ 1,016 Operating cash flows - finance leases ​ $ 9 ​ $ 15 Financing cash flows - finance leases ​ $ 96 ​ $ 102
Schedule of maturities of future minimum lease payments, operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2024 ​ $ 1,378 ​ $ 88 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 2,263 ​ ​ 88 Less: Imputed interest ​ ​ (173) ​ ​ (3) Lease liabilities ​ $ 2,090 ​ $ 85 ​
Schedule of maturities of future minimum lease payments, finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2024 ​ $ 1,378 ​ $ 88 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 2,263 ​ ​ 88 Less: Imputed interest ​ ​ (173) ​ ​ (3) Lease liabilities ​ $ 2,090 ​ $ 85 ​ ​

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of change in carrying amount of goodwill	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rx Segment Consumer Health Segment Consolidated ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of June 30, 2021 ​ $ 57,165 ​ $ 8,637 ​ $ 65,802 Goodwill impairment ​ (57,165) ​ (8,637) ​ (65,802) Balance as of June 30, 2022 ​ $ — ​ $ — ​ $ — ​
Schedule of finite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ $ 42,176 ​ $ (10,881) ​ $ — ​ $ 31,295 11.49 Acquired technology right ​ ​ 30,200 ​ ​ (4,054) ​ ​ — ​ ​ 26,146 ​ 14.75 Acquired product distribution rights ​ 9,182 ​ (4,678) ​ (2,975) ​ 1,529 1.00 ​ ​ ​ 81,558 ​ ​ (19,613) ​ ​ (2,975) ​ ​ 58,970 ​ 12.67 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 84,158 ​ $ (19,613) ​ $ (5,575) ​ $ 58,970 12.67 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Net Carrying ​ Remaining ​ Amount Amortization Impairment ​ Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (7,667) ​ ​ (3,224) ​ ​ 34,509 ​ 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (3,581) ​ (2,172) ​ ​ 5,601 ​ 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ 2,600 ​ — ​ ​ — ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 ​ 13.35
Schedule of Indefinite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ $ 42,176 ​ $ (10,881) ​ $ — ​ $ 31,295 11.49 Acquired technology right ​ ​ 30,200 ​ ​ (4,054) ​ ​ — ​ ​ 26,146 ​ 14.75 Acquired product distribution rights ​ 9,182 ​ (4,678) ​ (2,975) ​ 1,529 1.00 ​ ​ ​ 81,558 ​ ​ (19,613) ​ ​ (2,975) ​ ​ 58,970 ​ 12.67 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 84,158 ​ $ (19,613) ​ $ (5,575) ​ $ 58,970 12.67 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Net Carrying ​ Remaining ​ Amount Amortization Impairment ​ Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology right ​ ​ 45,400 ​ ​ (7,667) ​ ​ (3,224) ​ ​ 34,509 ​ 12.33 Acquired technology right ​ ​ 30,200 ​ ​ (2,278) ​ ​ — ​ ​ 27,922 ​ 15.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (3,581) ​ (2,172) ​ ​ 5,601 ​ 7.60 Other intangible assets ​ ​ 4,666 ​ ​ (3,004) ​ ​ (1,662) ​ ​ — ​ — ​ ​ ​ 91,620 ​ ​ (16,530) ​ ​ (7,058) ​ ​ 68,032 ​ 13.35 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ 2,600 ​ — ​ ​ — ​ 2,600 ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ ​ Total ​ $ 94,220 ​ $ (16,530) ​ $ (7,058) ​ $ 70,632 ​ 13.35
Schedule of future amortization expense	​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2024 ​ $ 6,518 2025 ​ ​ 4,989 2026 ​ ​ 4,989 2027 ​ ​ 4,989 2028 ​ ​ 4,989 Thereafter ​ ​ 32,496 Total future amortization expense ​ $ 58,970 ​

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Jun. 30, 2023
Accrued Liabilities, Current [Abstract]
Schedule of accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Accrued savings offers ​ $ 15,739 ​ $ 12,711 Accrued program liabilities ​ ​ 11,012 ​ ​ 9,468 Accrued compensation ​ ​ 5,675 ​ ​ 4,765 Accrued customer and product related fees ​ ​ 6,579 ​ ​ 7,817 Return reserve ​ 5,777 ​ 5,770 Other accrued liabilities ​ ​ 2,017 ​ ​ 3,656 Total accrued liabilities ​ $ 46,799 ​ $ 44,187
Schedule of the return reserve	​ ​ ​ ​ ​ ​ ​ ​ Return Reserve ​ ​ ​ (In thousands) ​ ​ ​ ​ Balance, June 30, 2021 ​ $ 6,367 Charges to expense ​ ​ 8,568 Payments ​ ​ (9,165) Balance, June 30, 2022 ​ $ 5,770 Charges to expense ​ ​ 8,353 Payments ​ ​ (8,346) Balance, June 30, 2023 ​ $ 5,777

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Jun. 30, 2023
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) ​ ​ ​ ​ ​ ​ ​ Fixed payment arrangement ​ $ 10,420 ​ $ 13,051 Operating lease liabilities ​ 2,090 ​ 3,317 Contingent value rights ​ ​ — ​ ​ 578 Contingent consideration ​ ​ — ​ ​ 396 Other ​ ​ 1,555 ​ ​ 815 Total other liabilities ​ ​ 14,065 ​ ​ 18,157 Less: current portion ​ ​ (7,090) ​ ​ (5,359) Total other liabilities, noncurrent ​ $ 6,975 ​ $ 12,798

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of long term debt	​ ​ ​ ​ ​ ​ June 30, ​ ​ 2023 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (925) Financing leases, maturing through May 2024 ​ ​ 85 Total debt ​ ​ 14,798 Less: current portion ​ ​ (85) Non-current portion of debt ​ $ 14,713
Schedule of future principal payments of long term debt	​ ​ ​ ​ ​ ​ June 30, ​ ​ (In thousands) 2024 ​ $ 85 2025 ​ ​ 15,638 Future principal payments ​ ​ 15,723 Less unamortized discount and issuance costs ​ ​ (925) Less current portion ​ ​ (85) Non-current portion of debt ​ $ 14,713 ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2023 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ $ 6,403 $ — $ — $ 6,403 Total ​ $ 6,403 $ — $ — ​ $ 6,403 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2022 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 396 $ — $ — $ 396 CVR liability ​ ​ 578 ​ — ​ — ​ 578 Derivative warrant liabilities ​ ​ 1,796 ​ ​ — ​ ​ — ​ ​ 1,796 Total ​ $ 2,770 $ — $ — ​ $ 2,770
Schedule of changes in Level 3 inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent ​ ​ Warrant ​ ​ Liability ​ Consideration ​ ​ Liability ​ ​ (In thousands) Balance as of June 30, 2022 $ 578 ​ $ 396 ​ $ 1,796 Included in earnings ​ (578) ​ ​ (391) ​ ​ (6,391) Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ Issues — ​ — ​ 10,998 Settlements — ​ (5) ​ — Balance as of June 30, 2023 $ — ​ $ — ​ $ 6,403 ​
Contingent Value Rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of significant assumptions used in valuation	Significant assumptions used in valuing the CVRs were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2023 ​ 2022 Leveraged Beta 0.84 ​ 0.85 ​ Market risk premium ​ 6.35 % ​ 6.22 % Risk-free interest rate ​ 5.47 % ​ 2.86 % Discount ​ 22.00 % ​ 20.50 % Company specific discount 10.00 % 10.00 %
Derivative Financial Instruments, Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of significant assumptions used in valuation	Significant assumptions used in valuing the derivative warrant liabilities at issuance date were as follows: ​ ​ ​ ​ ​ ​ ​ August 9, ​ 2022 Expected volatility 89.89 % Equivalent term (years) ​ 4.11 ​ Risk-free rate ​ 3.09 % Dividend yield ​ 0.00 % ​ ​ ​ ​ ​ ​ ​ ​ June 8, ​ 2023 Expected volatility 83.26 % Equivalent term (years) ​ 5.01 ​ Risk-free rate ​ 3.87 % Dividend yield ​ 0.00 % ​ Significant assumptions used in valuing ​ ​ ​ ​ ​ ​ June 30, ​ 2023 Expected volatility 83.42 % Equivalent term (years) ​ 3.59-4.95 ​ Risk-free rate ​ 4.13-4.40 % Dividend yield ​ 0.00 % ​ ​ ​ ​

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Provision for income taxes	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Current: ​ ​ ​ ​ ​ ​ Federal ​ $ 80 ​ $ — State ​ 46 ​ 7 Total current tax expense ​ 126 ​ 7 Deferred: ​ ​ ​ ​ Federal ​ (109) ​ (91) State ​ (17) ​ (26) Total deferred tax expense ​ (126) ​ (117) Provision for income taxes ​ $ — ​ $ (110)
Effective income tax rate reconciliation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2023 ​ ​ 2022 ​ ​ (In thousands) Tax at statutory rate ​ $ (3,581) ​ (22.30) % ​ $ (23,159) ​ (21.00) % State income taxes, net of federal benefit ​ ​ 16 ​ 0.10 % ​ ​ 601 ​ 0.55 % Permanent difference ​ ​ — ​ — % ​ ​ — ​ — % Stock based compensation ​ ​ — ​ — % ​ ​ 273 ​ 0.27 % Contingent consideration ​ ​ (193) ​ (1.20) % ​ ​ (155) ​ (0.14) % 162(m) limitation ​ ​ — ​ — % ​ ​ 76 ​ 0.08 % Goodwill impairment ​ ​ — ​ — % ​ ​ 9,733 ​ 8.83 % Transaction costs ​ ​ — ​ — % ​ ​ — ​ — % Change in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Remeasurement of deferred taxes ​ ​ — ​ — % ​ ​ — ​ — % Effect of phased-in tax rate ​ ​ — ​ — % ​ ​ — ​ — % Loss on debt extinguishment and interest expense ​ ​ — ​ — % ​ ​ — ​ — % Change in valuation allowance ​ ​ 3,641 ​ 22.68 % ​ ​ 12,472 ​ 11.31 % Derivative income ​ ​ — ​ — % ​ ​ — ​ — % Other ​ ​ 117 ​ 0.72 % ​ ​ 49 ​ 0.01 % Net income tax provision (benefit) ​ $ — ​ 0.00 % ​ $ (110) ​ (0.09) %
Deferred tax assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Deferred tax assets: ​ ​ ​ ​ ​ ​ Net operating loss carry forward ​ $ 114,265 ​ $ 114,443 Accrued Rebates ​ ​ 6,994 ​ ​ 5,944 Share-based compensation ​ 4,250 ​ 2,773 Accrued expenses ​ ​ 758 ​ ​ 817 R&D credits ​ 2,416 ​ 2,423 Interest ​ ​ 4,188 ​ ​ 2,975 Warrant Derivatives ​ ​ 1,504 ​ ​ — Section 174 Capitalization ​ ​ 836 ​ ​ — Inventory ​ 743 ​ 1,177 Lease liability ​ 492 ​ 799 Other ​ ​ 1,332 ​ ​ 1,301 Total deferred tax assets ​ ​ 137,778 ​ ​ 132,652 Less: valuation allowance ​ ​ (136,400) ​ ​ (128,966) Deferred tax assets, net of valuation allowance ​ ​ 1,378 ​ ​ 3,686 Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Intangibles ​ (845) ​ (2,717) Fixed Assets ​ (50) ​ (308) ROU asset ​ ​ (483) ​ ​ (788) Total deferred tax liabilities ​ ​ (1,378) ​ ​ (3,813) Net deferred tax liabilities ​ $ — ​ $ (127) ​
Tabular rollforward of gross unrecognized tax benefits	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2023 ​ 2022 ​ ​ (In thousands) Beginning balance ​ $ 2,822 ​ $ 3,435 Increase resulting from prior period tax positions ​ — ​ — Increase resulting from current period tax positions ​ ​ 246 ​ 34 Decrease resulting from current period tax positions ​ (120) ​ ​ (647) Ending balance ​ $ 2,948 ​ $ 2,822 ​

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 3,899 ​ $ 209.70 7.77 Granted 49,212 ​ ​ 4.00 Forfeited/Cancelled (172) ​ ​ 128.99 Expired (177) ​ ​ 131.39 Outstanding at June 30, 2023 52,762 ​ $ 18.37 9.06 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at June 30, 2023 3,022 ​ $ 225.74 6.17
Stock options outstanding	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Contractual ​ ​ ​ ​ ​ Range of ​ Number of ​ Average ​ Life of ​ Number of ​ Weighted Exercise ​ Options ​ Exercise ​ Options ​ Options ​ Average Prices ​ Outstanding ​ Price ​ Outstanding ​ Exercisable ​ Exercise Price $ 4.00 49,212 ​ $ 4.00 9.26 — ​ $ — $ 123.16 - 290.00 3,550 ​ $ 217.52 6.26 3,022 ​ $ 225.74 ​ ​ 52,762 ​ $ 18.37 9.06 3,022 ​ $ 225.74
Restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 80,373 ​ $ 148.91 Granted 6,825 ​ ​ 3.79 Vested (42,434) ​ ​ 126.98 Forfeited/Cancelled ​ (6,689) ​ ​ 135.66 Unvested at June 30, 2023 38,075 ​ $ 142.20
Restricted stock units activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2022 8,500 ​ $ 25.88 Vested (3,537) ​ ​ 26.26 Unvested at June 30, 2023 4,963 ​ $ 25.62
Stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ June 30, ​ ​ 2023 2022 ​ ​ (In thousands) Cost of sales ​ $ 28 ​ $ 31 Research and development ​ ​ 30 ​ ​ 536 Selling and marketing ​ ​ 23 ​ ​ 24 General and Administrative ​ 5,965 ​ 4,657 Total stock-based compensation expense ​ $ 6,046 ​ $ 5,248

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Jun. 30, 2023
Warrants and Rights Note Disclosure [Abstract]
Summary of warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2022 434,328 ​ $ 92.60 4.8 Warrants issued 6,028,331 ​ 1.61 5.0 Warrants exercised ​ (87,500) ​ ​ 0.02 ​ 5.0 Warrant adjusted ​ 181,461 ​ ​ 5.04 ​ 3.9 Warrants expired (18,568) ​ 2,011.56 — Outstanding June 30, 2023 6,538,052 ​ $ 4.42 4.71 ​

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of segment select financial information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ Rx ​ ​ Consumer Health ​ ​ Consolidated ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue, net $ 73,799 ​ $ 33,600 ​ $ 107,399 Loss from operations $ (7,358) ​ $ (9,707) ​ $ (17,065) ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization $ 6,271 ​ $ 1,116 ​ $ 7,387 Impairment and write-off expense $ 2,730 ​ $ 5,094 ​ $ 7,824 Stock based compensation $ 5,722 ​ $ 324 ​ $ 6,046 ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue, net $ 61,121 ​ $ 35,548 ​ $ 96,669 Loss from operations $ (92,441) ​ $ (17,465) ​ $ (109,906) ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization $ 7,821 ​ $ 1,557 ​ $ 9,378 Impairment expense $ 64,649 ​ $ 10,809 ​ $ 75,458 Stock based compensation $ 5,190 ​ $ 58 ​ $ 5,248 ​

Nature of Business and Financ_2

Nature of Business and Financial Condition - Segments (Details) - segment	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Nature of Business and Financ_3

Nature of Business and Financial Condition - Reverse Stock Split (Details)	Jan. 06, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock split, conversion ratio	0.05

Nature of Business and Financ_4

Nature of Business and Financial Condition - Product Information (Details)	12 Months Ended
	Jun. 30, 2023 item
Rx
Disaggregation of Revenue [Line Items]
Number of product portfolios	2

Nature of Business and Financ_5

Nature of Business and Financial Condition - General Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, cash equivalents and restricted cash	$ 22,985	$ 19,360	$ 49,901
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net	28,937	21,712
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	(17,051)	(108,779)
Retained Earnings (Accumulated Deficit) [Abstract]
Accumulated deficit	(304,129)	(287,078)
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash used in operations	$ (5,129)	$ (28,823)

Nature of Business and Financ_6

Nature of Business and Financial Condition - Going Concern (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jan. 26, 2022
Debt Instrument [Line Items]
Substantial Doubt about Going Concern, within One Year	true
Avenue Capital Loan, Term Loan
Debt Instrument [Line Items]
Face amount		$ 15

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Derivative warrant liabilities	$ 6,403	$ 1,796
Total liabilities	97,106	93,315
Additional paid-in capital	343,485	331,386
Accumulated deficit	(304,129)	(287,078)
Total stockholders' equity	$ 39,357	44,308	$ 137,568
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total liabilities		91,531
Additional paid-in capital		334,560
Accumulated deficit		(288,472)
Total stockholders' equity		46,092
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Derivative warrant liabilities		1,796
Total liabilities		1,784
Additional paid-in capital		(3,174)
Accumulated deficit		1,394
Total stockholders' equity		$ (1,784)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain on derivative warrant liability	$ 4,793	$ 1,605
Total other income, net	14	1,017
Loss before income tax	(17,051)	(108,889)
Net loss	$ (17,051)	$ (108,779)
Basic net loss per common share (in dollars per share)	$ (5.11)	$ (74.01)
Diluted net loss per common share (in dollars per share)	$ (5.11)	$ (74.01)
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain on derivative warrant liability		$ 211
Total other income, net		1,278
Loss before income tax		(110,283)
Net loss		$ (110,173)
Basic net loss per common share (in dollars per share)		$ (75)
Diluted net loss per common share (in dollars per share)		$ (75)
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain on derivative warrant liability		$ 1,394
Total other income, net		(261)
Loss before income tax		1,394
Net loss		$ 1,394
Basic net loss per common share (in dollars per share)		$ 0.99
Diluted net loss per common share (in dollars per share)		$ 0.99

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of common stock, net of issuance costs	$ 6,054	$ 8,854
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of common stock, net of issuance costs		11,652
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of common stock, net of issuance costs		$ (2,798)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss	$ (17,051)	$ (108,779)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Gain on derivative warrant liability	$ (4,793)	(1,605)
Previously Reported
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss		(110,173)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Gain on derivative warrant liability		(211)
Revision of Prior Period, Error Correction, Adjustment
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss		1,394
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Gain on derivative warrant liability		$ (1,394)

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating Income (Loss) [Abstract]
Loss from operations	$ (17,065)	$ (109,906)
Rx
Operating Income (Loss) [Abstract]
Loss from operations	(7,358)	(92,441)
Consumer Health Segment
Operating Income (Loss) [Abstract]
Loss from operations	$ (9,707)	$ (17,465)

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Allowances	$ 2,990	$ 2,507	$ 2,149
Allowance for doubtful accounts	0	0
Allowance for discounts	1,778	1,301	1,133
Allowance for chargebacks	$ 1,212	$ 1,206	$ 1,016

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Opening balance	$ 24,219	$ 30,325
Increase (decrease)	7,708	(6,106)
Closing balance	$ 31,927	$ 24,219

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Allowance for discount, beginning balance	$ 1,301	$ 1,133
Allowance for discount, charges to expense	9,074	6,760
Allowance for discount, payments	(8,597)	(6,592)
Allowance for discount, ending balance	1,778	1,301
Allowance for chargeback, beginning balance	1,206	1,016
Allowance for chargeback, charges to expense	4,554	4,598
Allowance for chargeback, payments	(4,548)	(4,408)
Allowance for chargeback, ending balance	1,212	1,206
Total allowance, beginning balance	2,507	2,149
Total allowance, charges to expense	13,628	11,358
Total allowance, payments	(13,145)	(11,000)
Total allowance, ending balance	$ 2,990	$ 2,507

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Property and Equipment (Details)	Jun. 30, 2023
Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	2 years
Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Furniture and Fixtures | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	2 years
Furniture and Fixtures | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Accounts receivable, credit terms, low end of range	40 days
Accounts receivable, credit terms, high end of range	60 days

Summary of Significant Accou_14

Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer A
Concentration Risk [Line Items]
Concentration risk (as a percent)	43%	41%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer B
Concentration Risk [Line Items]
Concentration risk (as a percent)	18%	20%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer C
Concentration Risk [Line Items]
Concentration risk (as a percent)	17%	18%
Accounts Receivable | Credit Concentration Risk | Customer A
Concentration Risk [Line Items]
Concentration risk (as a percent)	50%	52%
Accounts Receivable | Credit Concentration Risk | Customer B
Concentration Risk [Line Items]
Concentration risk (as a percent)	19%	25%
Accounts Receivable | Credit Concentration Risk | Customer C
Concentration Risk [Line Items]
Concentration risk (as a percent)	14%	18%

Summary of Significant Accou_15

Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Marketing and Advertising Expense [Abstract]
Advertising costs	$ 11.1	$ 13.6

Summary of Significant Accou_16

Summary of Significant Accounting Policies - Segment Information (Details) - segment	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Summary of Significant Accou_17

Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	6,636,773	532,104
Warrants to Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	6,538,052	434,328
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	52,762	3,899
Employee Unvested Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	40,996	85,377
Employee Unvested Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,963	8,500

Summary of Significant Accou_18

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)	Jun. 30, 2023
Accounting Standards Update 2021-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false

Revenues from Contracts with _3

Revenues from Contracts with Customers - General Information (Details)	12 Months Ended
	Jun. 30, 2023 segment product	Jun. 30, 2022 segment
Disaggregation of Revenue [Line Items]
Number of Reportable Segments | segment	2	2
Consumer Health Portfolio | Minimum
Disaggregation of Revenue [Line Items]
Number of products | product	10

Revenues from Contracts with _4

Revenues from Contracts with Customers - Revenues by Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 107,399	$ 96,669
Rx
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	73,799	61,121
Consumer Health Segment
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 33,600	$ 35,548

Revenues from Contracts with _5

Revenues from Contracts with Customers - Revenues by Product Portfolio (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 107,399	$ 96,669
ADHD
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 46,855	$ 42,855
Reporting Unit, Name of Segment	Rx	Rx
Pediatric
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 25,377	$ 16,084
Reporting Unit, Name of Segment	Rx	Rx
Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 1,567	$ 2,182
Reporting Unit, Name of Segment	Rx	Rx
Consumer Health Portfolio
Disaggregation of Revenue [Line Items]
Reporting Unit, Name of Segment	Consumer Health Segment	Consumer Health Segment
Rx
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 73,799	$ 61,121

Revenues from Contracts with _6

Revenues from Contracts with Customers - Revenues by Geographic Location (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 107,399	$ 96,669
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	106,918	94,606
Non-US
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 481	$ 2,063

Inventories - Tabular Disclosur

Inventories - Tabular Disclosure (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Inventory, Net [Abstract]
Raw materials	$ 1,301	$ 1,814
Work in process	2,956	1,838
Finished goods	7,738	7,197
Inventories	$ 11,995	$ 10,849

Inventories - Inventory Write-d

Inventories - Inventory Write-down (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Production Related Impairments or Charges [Abstract]
Inventory write-down	$ 2,351	$ 2,186
Inventory write-down and impairment		$ 4,200

Property and Equipment - Tabula

Property and Equipment - Tabular Disclosure (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 5,496	$ 5,446
Less accumulated depreciation and amortization	(3,681)	(2,421)
Property and equipment, net	1,815	3,025
Manufacturing Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	2,433	2,487
Leasehold Improvements
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	999	999
Office Equipment, Furniture and Other
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	1,125	1,128
Lab Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	832	$ 832
Asset under Construction
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 107

Property and Equipment - Deprec

Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Depreciation, Depletion and Amortization [Abstract]
Depreciation expense	$ 1.3	$ 1.6

Property and Equipment - Gain (

Property and Equipment - Gain (Loss) on Disposal (Details) $ in Millions	12 Months Ended
	Jun. 30, 2022 USD ($)
Gain (Loss) on Disposition of Property Plant Equipment [Abstract]
Gain (loss) on sale of equipment	$ 0.1

Property and Equipment - Impair

Property and Equipment - Impairment (Details) - Manufacturing Equipment $ in Millions	12 Months Ended
	Jun. 30, 2022 USD ($)
Impairment, Long-Lived Asset, Held-for-Use [Abstract]
Impairment charge	$ 0.2
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income	Impairment expense

Leases - General Information (D

Leases - General Information (Details)	12 Months Ended
	Jun. 30, 2023 USD ($)	May 31, 2023 ft²	Apr. 30, 2023 ft²	Jun. 30, 2022 USD ($)	Mar. 19, 2021 USD ($)
Lessee, Operating Lease, Description [Abstract]
Lessee, Operating Lease, Existence of Option to Extend	true
Operating lease right-of-use asset	$ 2,054,000			$ 3,271,000
Operating lease liabilities	2,090,000			3,317,000
Expansion date
Lessee, Operating Lease, Description [Abstract]
Rent receivable from sublease property	20,500
Expiration of sublease
Lessee, Operating Lease, Description [Abstract]
Rent receivable from sublease property	$ 70,686
Office Space and Manufacturing Facilities, Grand Prairie, Texas
Lessee, Operating Lease, Description [Abstract]
Operating lease right-of-use asset					$ 3,500,000
Operating lease liabilities					$ 3,500,000
Operating lease, borrowing rate (as a percent)					6.70%
Area of Sublease Property | ft²			22,909
Remaining Area of Sublease Property | ft²		54,203
Lessee, Finance Lease, Description [Abstract]
Finance leases, interest rate (as a percent)					5.90%
Principal Office, Denver, Colorado
Lessee, Operating Lease, Description [Abstract]
Operating lease right-of-use asset				$ 300,000
Lessee, operating lease, term of contract				5 years

Leases - Net Lease Cost (Detail

Leases - Net Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Lease, Cost [Abstract]
Operating lease cost	$ 1,402	$ 1,299
Short-term lease cost	97	152
Amortization of leased assets	66	73
Interest on lease liabilities	9	14
Total net lease cost	$ 1,574	$ 1,538

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 2,054	$ 3,271
Finance lease assets	$ 159	$ 256
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property and equipment, net	Property and equipment, net
Total leased assets	$ 2,213	$ 3,527
Current portion of operating lease liabilities	$ 1,258	$ 1,227
Operating Lease, Liability, Current, Statement of Financial Position	Other current liabilities	Other current liabilities
Finance leases, current	$ 85	$ 96
Finance Lease, Liability, Current, Statement of Financial Position	Current portion of debt	Current portion of debt
Operating lease liabilities, net of current portion	$ 832	$ 2,090
Operating Lease, Liability, Noncurrent, Statement of Financial Position	Other non-current liabilities	Other non-current liabilities
Finance leases, long-term		$ 84
Finance Lease, Liability, Noncurrent, Statement of Financial Position	Debt, net of current portion	Debt, net of current portion
Total lease liabilities	$ 2,175	$ 3,497

Leases - Remaining Lease Term a

Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)	Jun. 30, 2023	Jun. 30, 2022
Lessee Disclosure [Abstract]
Operating lease assets, weighted-average remaining lease term	1 year 8 months 19 days	2 years 7 months 17 days
Finance lease assets, weighted-average remaining lease term	10 months 13 days	1 year 8 months 23 days
Operating lease assets, weighted-average discount rate	7.78%	7.48%
Finance lease assets, weighted-average discount rate	6.54%	6.43%

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows - operating leases	$ 1,436	$ 1,016
Cash Flow, Investing Activities, Lessee [Abstract]
Operating cash flows - finance leases	9	15
Cash Flow, Financing Activities, Lessee [Abstract]
Financing cash flows - finance leases	$ 96	$ 102

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2024	$ 1,378
2025	749
2026	90
2027	46
Total lease payments	$ 2,263

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 2,263
Less: Imputed interest	(173)
Lease liabilities	$ 2,090	$ 3,317

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Finance Lease, Liability, Payment, Due [Abstract]
2024	$ 88
Total lease payments	$ 88

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Finance Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 88
Less: Imputed interest	(3)
Lease liabilities	$ 85

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 65,802
Goodwill impairment	(65,802)
Goodwill, ending balance	0
Consumer Health Segment
Goodwill [Roll Forward]
Goodwill, beginning balance	8,637
Goodwill impairment	(8,637)
Rx Segment
Goodwill [Roll Forward]
Goodwill, beginning balance	57,165
Goodwill impairment	$ (57,165)

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 81,558	$ 91,620
Accumulated amortization	(19,613)	(16,530)
Finite-lived intangible assets, accumulated impairment	(2,975)	(7,058)
Total future amortization expense	58,970	68,032
Acquired product technology right
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	42,176	45,400
Accumulated amortization	(10,881)	(7,667)
Finite-lived intangible assets, accumulated impairment		(3,224)
Total future amortization expense	31,295	34,509
Acquired technology right
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	30,200	30,200
Accumulated amortization	(4,054)	(2,278)
Total future amortization expense	26,146	27,922
Acquired product distribution rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	9,182	11,354
Accumulated amortization	(4,678)	(3,581)
Finite-lived intangible assets, accumulated impairment	(2,975)	(2,172)
Total future amortization expense	$ 1,529	5,601
Other intangible assets
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount		4,666
Accumulated amortization		(3,004)
Finite-lived intangible assets, accumulated impairment		$ (1,662)

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details) - Weighted Average	Jun. 30, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	12 years 8 months 1 day	13 years 4 months 6 days
Acquired product technology right
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	11 years 5 months 26 days	12 years 3 months 29 days
Acquired technology right
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	14 years 9 months	15 years 9 months
Acquired product distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	1 year	7 years 7 months 6 days

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 81,558	$ 91,620
Indefinite-lived intangible assets	2,600	2,600
Intangible assets, gross carrying amount	84,158	94,220
Accumulated amortization	(19,613)	(16,530)
Finite-lived intangible assets, accumulated impairment	(2,975)	(7,058)
Indefinite-lived intangible assets, accumulated impairment	(2,600)
Impairment	(5,575)	(7,058)
Intangible assets, net carrying amount	$ 58,970	$ 70,632

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2024	$ 6,518
2025	4,989
2026	4,989
2027	4,989
2028	4,989
Thereafter	32,496
Total future amortization expense	$ 58,970	$ 68,032

Goodwill and Other Intangible_8

Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)	12 Months Ended
	Jun. 30, 2023
Supply and Distribution Agreement, Tris Pharma, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years

Goodwill and Other Intangible_9

Goodwill and Other Intangible Assets - Estimated Useful Life (Details)	12 Months Ended
	Jun. 30, 2023
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	1 year
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	20 years
Product Technology Right | Attention Deficit Hyperactivity Disorder Portfolio
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	17 years

Goodwill and Other Intangibl_10

Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details) $ in Millions	1 Months Ended	12 Months Ended
	Feb. 29, 2020 product item	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Business Acquisition [Line Items]
Impairment of intangible assets, finite-lived			$ 4.9
Consumer Health Segment
Business Acquisition [Line Items]
Impairment of intangible assets, finite-lived			$ 2.2
Innovus Pharmaceuticals, Inc
Business Acquisition [Line Items]
Number of products acquired | product	35
Number of registered trademarks and or patent rights and customer lists acquired | item	300
Innovus Pharmaceuticals, Inc | Consumer Health Segment
Business Acquisition [Line Items]
Impairment of intangible assets, finite-lived		$ 3

Goodwill and Other Intangibl_11

Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Amortization [Abstract]
Amortization expense	$ 6.1	$ 7.8

Goodwill and Other Intangibl_12

Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		$ 4.9
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income		Impairment expense
Neos Therapeutics, Inc.
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	$ 2.6
Consumer Health Segment
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		$ 2.2
Consumer Health Segment | Innovus Pharmaceuticals, Inc
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived	$ 3
Trade Names
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		0.2
AcipHex
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		2.6
ZolpiMist
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		1.4
Tussionex
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		0.5
Cefaclor
Asset Impairment Charges [Abstract]
Impairment of intangible assets, finite-lived		$ 0.2

Goodwill and Other Intangibl_13

Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 0	$ 0	$ 65,802

Accrued Liabilities - General I

Accrued Liabilities - General Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Accrued savings offers	$ 15,739	$ 12,711
Accrued program liabilities	11,012	9,468
Accrued compensation	5,675	4,765
Accrued customer and product related fees	6,579	7,817
Return reserve	5,777	5,770
Other accrued liabilities	2,017	3,656
Total accrued liabilities	$ 46,799	$ 44,187

Accrued Liabilities - Return Re

Accrued Liabilities - Return Reserve (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Return reserve, beginning balance	$ 5,770	$ 6,367
Return reserve, charges to expense	8,353	8,568
Return reserve, payments	(8,346)	(9,165)
Return reserve, ending balance	$ 5,777	$ 5,770

Other Liabilities - Components

Other Liabilities - Components (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Other Liabilities, Unclassified [Abstract]
Fixed payment arrangements	$ 10,420	$ 13,051
Operating lease liabilities	2,090	3,317
Contingent value rights	0	578
Contingent consideration		396
Other	1,555	815
Total other liabilities	$ 14,065	$ 18,157

Other Liabilities - Classificat

Other Liabilities - Classification (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Other Liabilities [Abstract]
Total other liabilities	$ 14,065	$ 18,157
Less: current portion	(7,090)	(5,359)
Total other liabilities, noncurrent	$ 6,975	$ 12,798

Other Liabilities - Fixed Payme

Other Liabilities - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended
	May 12, 2022 USD ($) payment	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 10,420	$ 13,051
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number | agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									$ 15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements		$ 3,000
Fixed payment arrangements, quarterly payment amount, payments, number | payment								6
Fixed payment arrangements, quarterly payment amount								$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)									15%
Fixed payment arrangements, monthly variable payment amount, minimum						100			$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026									$ 9,300
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements						6,600
Fixed payment arrangements, liability, reduction	$ 8,000
Fixed payment arrangements, installment payments, number | payment	3
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc | Minimum
Other Commitments [Line Items]
Fixed payment arrangements	$ 6,000
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc | Maximum
Other Commitments [Line Items]
Fixed payment arrangements	9,000
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Fixed payment arrangements, current						1,700
Fixed payment arrangements, noncurrent						$ 2,100
Issues, fixed payment arrangements	$ 7,600

Other Liabilities - Supply and

Other Liabilities - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	12 Months Ended
	Jun. 30, 2023 USD ($) item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item	70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit	$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount	2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation	3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount	$ 40,000,000

Other Liabilities - Contingent

Other Liabilities - Contingent Value Rights (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Feb. 29, 2020
Other Liabilities Disclosure [Abstract]
Contingent value rights, business combination, contingent consideration, milestone payable, amount, maximum	$ 5,000				$ 16,000
Contingent value rights, business combination, contingent consideration, milestone payable, shares, maximum (in shares)					470,000
Contingent Value Rights payouts (in shares)			5,160	6,191
Contingent value rights	0	$ 578
Contingent value rights, gain (loss) for change in fair value during period	$ 600	$ 800

Other Liabilities - Contingen_2

Other Liabilities - Contingent Consideration - Business Combination (Details) - USD ($) $ in Millions	Jun. 30, 2023	Jun. 30, 2022	Feb. 29, 2020
Business Acquisition [Line Items]
Contingent consideration	$ 0	$ 0.4
Innovus Pharmaceuticals, Inc
Business Acquisition [Line Items]
Business combination, contingent consideration, product related, milestone payable, amount			$ 0.2
Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent)			30%

Other Liabilities - Contingen_3

Other Liabilities - Contingent Consideration - Other than Business Combination (Details) - USD ($)		12 Months Ended
	May 12, 2022	Jun. 30, 2022	Jun. 30, 2023
Other Commitments [Line Items]
Other current liabilities		$ 5,359,000	$ 7,090,000
Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period	$ 8,500,000
Contingent consideration other than from business combination, gain (loss) for change in fair value during period		900,000
Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period		600,000
Other current liabilities		50,000
Contingent consideration other than from business combination, gain (loss) for change in fair value during period		$ 600,000

Other Liabilities - Contingen_4

Other Liabilities - Contingent Consideration - Total (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Other Liabilities Disclosure [Abstract]
Business combination, contingent consideration, and contingent consideration other than from business combination, gain (loss) for change in fair value during period	$ 0.4	$ (0.5)
Contingent consideration	$ 0	$ 0.4

Line of Credit (Details)

Line of Credit (Details) $ in Thousands			1 Months Ended	12 Months Ended
	Mar. 24, 2023 USD ($)	Jan. 26, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2023 USD ($) D	Jun. 30, 2022 USD ($)
Short-Term Debt [Line Items]
Short-term line of credit				$ 1,563	$ 3,813
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans
Short-Term Debt [Line Items]
Maximum borrowing capacity, increase (decrease)	$ 2,000
Maximum borrowing capacity	$ 14,500	$ 12,500	$ 25,000
Basis spread on variable rate (as a percent)			4.50%
Debt instrument, maturity date		Jan. 26, 2025	May 11, 2022
Availability block		$ 3,500	$ 1,000
Termination fee before 26 January 2023 (as a percent)				2%
Termination fee after 26 January 2023, but before 26 January 2024 (as a percent)				1%
Termination fee after 26 January 2024, but on or before 26 January 2025 (as a percent)				0.50%
Notice period | D				5
Interest expense including amortization of deferred financing costs				$ 700	400
Short-term line of credit				1,600	3,800
Unused line of credit				$ 9,300
Unamortized deferred financing costs		$ 100			$ 100
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Short-Term Debt [Line Items]
Unused capacity commitment fee (as a percent)			0.50%
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans
Short-Term Debt [Line Items]
Maximum borrowing capacity			$ 2,500
Maximum borrowing capacity, percentage of eligible accounts receivable (as a percent)			85%

Long-term Debt - Narrative (Det

Long-term Debt - Narrative (Details) - USD ($) $ in Thousands		7 Months Ended	12 Months Ended
	Jan. 26, 2022	Jan. 26, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 19, 2021
Debt Instrument [Line Items]
Long-term, final payment fee			$ 638
Gain (Loss) on extinguishment of debt				$ 169
Deerfield Facility
Debt Instrument [Line Items]
Carrying amount of the remaining outstanding debt					$ 16,600
Fair value of the remaining outstanding debt					17,400
Unamortized premium					$ 800
Interest expense		$ 800
Gain (Loss) on extinguishment of debt				200
Avenue Capital Loan, Term Loan
Debt Instrument [Line Items]
Debt instrument, minimum variable rate before basis spread (as a percent)	3.25%
Debt instrument, basis spread on variable rate (as a percent)	7.40%
Face amount	$ 15,000	$ 15,000
Debt Instrument, Interest Payment Term	18 months
Debt Instrument, Interest Payment Extension Term	6 months
Interest Only Period Further Extension Term	6 months
Debt Instrument, Term of Trailing Months Revenue	12 months
Debt Instrument Prepayment Fee Percentage	3%
Loan Processing Fee			$ 400
Debt Instrument, Interest Rate, Effective Percentage			16.59%
Interest expense including amortization of deferred financing costs			$ 2,700	$ 900
Avenue Capital Loan, Term Loan | Event Occurs after January 26, 2023, but on or before January 26, 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage	2%
Avenue Capital Loan, Term Loan | Event Occurs after January 26, 2024, but on or before January 26, 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage	1%

Long-term Debt - Warrants (Deta

Long-term Debt - Warrants (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 07, 2022	Jan. 26, 2022	Oct. 25, 2022	Jun. 29, 2022
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Mar. 07, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 24.20		$ 8.60
Share price (in dollars per share)	$ 25
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 24.20
Fair value of warrants		$ 0.6
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022 | Minimum
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 24.20

Long-term Debt - Composition (D

Long-term Debt - Composition (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Long-term debt, due on January 26, 2025	$ 15,000
Long-term, final payment fee	638
Unamortized discount	(925)
Financing leases, maturing through May 2024	85
Total debt	14,798
Less current portion	(85)	$ (96)
Non-current portion of debt	$ 14,713	$ 14,279

Long-term Debt - Future Princip

Long-term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
2024	$ 85
2025	15,638
Future principal payments	15,723
Less unamortized discount and issuance costs	(925)
Less current portion	(85)	$ (96)
Non-current portion of debt	$ 14,713	$ 14,279

Fair Value Measurements - Recur

Fair Value Measurements - Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration		$ 396
CVR liability	$ 0	$ 578
Derivative Liability, Statement of Financial Position	Derivative warrant liabilities	Derivative warrant liabilities
Fair Value, Recurring
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration		$ 396
CVR liability		578
Derivative warrant liabilities	$ 6,403	1,796
Total	6,403	2,770
Fair Value, Recurring | Fair Value, Inputs, Level 3
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration		396
CVR liability		578
Derivative warrant liabilities	6,403	1,796
Total	$ 6,403	$ 2,770

Fair Value Measurements - Unobs

Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2023 USD ($)
Contingent Value Rights
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 578
Included in earnings	$ (578)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 396
Included in earnings	$ (391)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period
Settlements	$ (5)
Derivative Financial Instruments, Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1,796
Included in earnings	$ (6,391)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Gain on derivative warrant liability
Issues	$ 10,998
Ending balance	$ 6,403

Fair Value Measurements - Valua

Fair Value Measurements - Valuation Assumptions (Details)	Jun. 30, 2023 Y	Jun. 08, 2023 Y	Aug. 09, 2022 Y	Jun. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Valuation Technique	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember
Measurement Input, Leveraged Beta
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.84			0.85
Measurement Input, Market Risk Premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0635			0.0622
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.8342	0.8326	0.8989
Measurement Input, Expected Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		5.01	4.11
Measurement Input, Expected Term | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.59
Measurement Input, Expected Term | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.95
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0547			0.0286
Derivative liability, measurement input		0.0387	0.0309
Measurement Input, Risk Free Interest Rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0413
Measurement Input, Risk Free Interest Rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0440
Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.2200			0.2050
Measurement Input, Discount for Lack of Marketability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.1000			0.1000
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0	0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	May 31, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed Payment Arrangements	$ 10,420	$ 13,051
Impairment of intangible assets excluding goodwill	$ 5,600	7,100
Goodwill impairment		$ 65,802
Fair Value, Nonrecurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed Payment Arrangements			$ 7,600
Measurement Input, Discount Rate | Minimum | Fair Value, Nonrecurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed payment arrangements, measurement input	0.100
Measurement Input, Discount Rate | Maximum | Fair Value, Nonrecurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fixed payment arrangements, measurement input	0.154

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense (benefit)	$ 0	$ (110)

Income Taxes - Consolidated Bal

Income Taxes - Consolidated Balance Sheet (Details) $ in Millions	Jun. 30, 2023 USD ($)
Taxes Payable, Current [Abstract]
Income tax payable	$ 0.1
Other Noncurrent Assets
Assets, Noncurrent [Abstract]
Deferred tax assets	0.1
Other Noncurrent Liabilities
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Deferred tax liabilities	$ 0.1

Income Taxes - Section 382 Limi

Income Taxes - Section 382 Limitation (Details) $ in Millions	Jun. 30, 2023 USD ($)
Income Tax Disclosure [Abstract]
Post-change NOL determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation	$ 12
Disallowed recognized built-in loss, carried forward as an operating loss	$ 0.3

Income Taxes - Operating Loss C

Income Taxes - Operating Loss Carry Forwards (Details) - Domestic Tax Authority - USD ($) $ in Millions	Jun. 30, 2023	Jun. 30, 2022
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 504	$ 503.2
Operating loss carryforwards not subject to expiration	$ 172

Income Taxes - Tax Credit Carry

Income Taxes - Tax Credit Carry Forwards (Details) $ in Millions	Jun. 30, 2023 USD ($)
Research Tax Credit Carryforward
Tax Credit Carryforward [Line Items]
Tax credit carry forward	$ 3

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal	$ 80
State	46	$ 7
Total current tax expense	126	7
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal	(109)	(91)
State	(17)	(26)
Total deferred tax expense	(126)	(117)
Provision for income taxes	$ 0	$ (110)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax at statutory rate	$ (3,581)	$ (23,159)
State income taxes, net of federal benefit	16	601
Stock based compensation		273
Contingent consideration	(193)	(155)
162(m) limitation		76
Goodwill impairment		9,733
Change in valuation allowance	3,641	12,472
Other	117	49
Provision for income taxes	$ 0	$ (110)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Tax at statutory rate (as a percent)	(22.30%)	(21.00%)
State income taxes, net of federal benefit (as a percent)	0.10%	0.55%
Stock based compensation (as a percent)		0.27%
Contingent consideration (as a percent)	(1.20%)	(0.14%)
162(m) limitation (as a percent)		0.08%
Goodwill impairment (as a percent)		8.83%
Change in valuation allowance (as a percent)	22.68%	11.31%
Other (as a percent)	0.72%	0.01%
Net income tax provision (benefit) (as a percent)	0%	(0.09%)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Deferred Tax Assets, Net of Valuation Allowance [Abstract]
Net operating loss carry forward	$ 114,265	$ 114,443
Accrued Rebates	6,994	5,944
Share-based compensation	4,250	2,773
Accrued expenses	758	817
R&D credits	2,416	2,423
Interest	4,188	2,975
Warrant Derivatives	1,504
Section 174 Capitalization	836
Inventory	743	1,177
Lease liability	492	799
Other	1,332	1,301
Total deferred tax assets	137,778	132,652
Less: valuation allowance	(136,400)	(128,966)
Deferred tax assets, net of valuation allowance	1,378	3,686
Deferred Tax Liabilities, Net [Abstract]
Intangibles	(845)	(2,717)
Fixed assets	(50)	(308)
ROU asset	(483)	(788)
Total deferred tax liabilities	$ (1,378)	(3,813)
Net deferred tax liabilities		$ (127)

Income Taxes - Deferred Tax A_2

Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details) $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($)
Income Tax Disclosure [Abstract]
Goodwill impairment, decrease in net deferred tax liabilities	$ 0.1
Income tax benefit resulting from decreased net deferred tax liabilities	$ 0.1

Income Taxes - Deferred Tax A_3

Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details) $ in Millions	Jun. 30, 2023 USD ($)
Other Noncurrent Liabilities
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Deferred tax liabilities	$ 0.1

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits - General Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 2,948	$ 2,822	$ 3,435

Income Taxes - Unrecognized T_2

Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 2,822	$ 3,435
Increase resulting from current period tax positions	246	34
Decrease resulting from current period tax positions	(120)	(647)
Ending balance	$ 2,948	$ 2,822

Stockholders Equity - Common an

Stockholders Equity - Common and Preferred Stock (Details) - $ / shares	Jun. 30, 2023	Jun. 30, 2022
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	5,517,174	1,928,941
Common stock, shares outstanding (in shares)	5,517,174	1,928,941
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Stockholders Equity - Restricte

Stockholders Equity - Restricted Stock (Details) - shares	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	5,517,174	1,928,941
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	40,996

Stockholders Equity - Stock Off

Stockholders Equity - Stock Offerings (Details) - USD ($) $ in Thousands				12 Months Ended
	Jun. 08, 2023	Aug. 11, 2022	Mar. 07, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 28, 2021	Jun. 04, 2021	Jun. 17, 2020
Subsidiary, Sale of Stock [Line Items]
Net proceeds from issuance of stock				$ 15,575	$ 11,694
Shelf Registration Statement, 2020 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized								$ 100,000
Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement
Subsidiary, Sale of Stock [Line Items]
At-the-market sales agreement, amount authorized							$ 30,000
Issuance of common stock (in shares)				699,929
Net proceeds from issuance of stock				$ 3,000
Underwriting discounts, commissions, and other offering expenses				100
Shelf Registration Statement, 2021 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized						$ 100,000
Shelf registration, remaining amount available for sale				$ 82,400
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)			151,500
Proceeds from issuance of common stock and warrants			$ 7,600
Commission and other costs			$ 800
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)		1,075,290
Proceeds from issuance of common stock and warrants		$ 10,000
Underwriting discounts, commissions, and other offering expenses		$ 900
Securities Purchase Agreement, 2023, Private Offering, June 2023
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	1,743,695
Proceeds from issuance of common stock and warrants	$ 4,000
Commission and other costs	600
Proceeds from issuance of common stock and warrants, net of issuance costs	$ 3,400

Stockholders Equity - Warrants

Stockholders Equity - Warrants (Details) - USD ($) $ / shares in Units, $ in Millions	Jun. 08, 2023	Aug. 11, 2022	Mar. 07, 2022	Jan. 26, 2022	Jun. 30, 2023	Nov. 30, 2022	Sep. 07, 2022	Aug. 31, 2022
Warrants to Purchase Common Stock, Equity Classified, March 2022
Class of Warrant or Right [Line Items]
Fair value of warrants			$ 2.8
Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)			151,500
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 0.002
Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable			Sep. 07, 2022
Class of warrant or right, number of securities called by warrants or right (in shares)			333,300
Class of warrant or right, number of securities called by each warrant or right (in shares)			1.1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 26
Warrants and rights outstanding, term			5 years				5 years
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable				Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 24.20
Fair value of warrants				$ 0.6
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Aug. 11, 2022
Class of warrant or right, offering price (in dollars per share)		$ 8.58
Fair value of warrants		$ 6
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		87,500
Class of warrant or right, number of securities called by each warrant or right (in shares)		1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 0.02						$ 0.001
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares)		1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 8.60			$ 3.30	$ 2.32
Warrants and rights outstanding, term		5 years
Warrants to Purchase Common Stock, Liability Classified, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Jun. 08, 2023
Fair value of warrants	$ 5
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	430,217
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.0001
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)	1.5899
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	0.0001
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)	$ 1.59
Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	2,173,912
Warrants and rights outstanding, term	5 years
Class of warrant, term of expiration after closing price of common stock	30 days
Class of warrant or right, percentage of exercise price equaling common stock	200%
Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	2,173,912
Warrants and rights outstanding, term	5 years
Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA	30 days
Adjusted earnings before interest, taxes, depreciation, and amortization	$ 12

Equity Incentive Plans - Genera

Equity Incentive Plans - General Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	May 18, 2023	Jun. 30, 2022	Apr. 19, 2021	Mar. 19, 2021	Feb. 13, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	52,762		3,899
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)	4,963		8,500
Aytu 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)						250,000
Number of shares available for grant (in shares)		0
Aytu 2015 Plan | Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Aytu 2015 Plan | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)	38,075		80,373
Total fair value	$ 0.2
Aytu 2015 Plan | Restricted Stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Aytu 2015 Plan | Restricted Stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	10 years
Aytu 2015 Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Neos 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)					3,486
Number of shares available for grant (in shares)		0		5,272
Neos 2015 Plan | Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Neos 2015 Plan | Share-Based Payment Arrangement, Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Neos 2015 Plan | Share-Based Payment Arrangement, Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Neos 2015 Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)					1,786
2023 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)	287,155	87,155
Common stock, capital shares reserved for future issuance		200,000

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Options (Details) - $ / shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding, beginning balance (in shares)	3,899
Granted (in shares)	49,212	0
Forfeited/cancelled (in shares)	(172)
Expired (in shares)	(177)
Number of options outstanding, ending balance (in shares)	52,762	3,899
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price outstanding, beginning balance (in dollars per share)	$ 209.70
Granted (in dollars per share)	4
Forfeited/cancelled (in dollars per share)	128.99
Expired (in dollars per share)	131.39
Weighted average exercise price outstanding, ending balance (in dollars per share)	$ 18.37	$ 209.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life (Year)	9 years 21 days		7 years 9 months 7 days
Number of options exercisable	3,022
Weighted average exercise price exercisable (in dollars per share)	$ 225.74
Weighted average remaining contractual life in years exercisable	6 years 2 months 1 day

Equity Incentive Plans - Range

Equity Incentive Plans - Range of Exercise Prices (Details)	12 Months Ended
	Jun. 30, 2023 $ / shares shares
Equity Incentive Plan
Number of options outstanding | shares	52,762
Weighted average exercise price	$ 18.37
Weighted average remaining contractual life of options outstanding	9 years 21 days
Number of options exercisable | shares	3,022
Weighted average exercise price	$ 225.74
Exercise Price Range 1
Equity Incentive Plan
Range of exercise prices	$ 4
Number of options outstanding | shares	49,212
Weighted average exercise price	$ 4
Weighted average remaining contractual life of options outstanding	9 years 3 months 3 days
Exercise Price Range 2
Equity Incentive Plan
Number of options outstanding | shares	3,550
Weighted average exercise price	$ 217.52
Weighted average remaining contractual life of options outstanding	6 years 3 months 3 days
Number of options exercisable | shares	3,022
Weighted average exercise price	$ 225.74
Exercise Price Range 2 | Minimum
Equity Incentive Plan
Range of exercise prices	123.16
Exercise Price Range 2 | Maximum
Equity Incentive Plan
Range of exercise prices	$ 290

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock - General Information (Details) - Restricted Stock - Aytu 2015 Plan - $ / shares		12 Months Ended
	Aug. 02, 2021	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)		38,075	80,373
Granted (in shares)		6,825
Granted, weighted average grant date fair value (in dollars per share)		$ 3.79
Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	6,825
Management | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, weighted average grant date fair value (in dollars per share)		3.31
Management | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, weighted average grant date fair value (in dollars per share)		$ 13.4
Management | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		33.33%
Management | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%
Management | Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%
Management | Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%
Management | Tranche Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%
Management | Tranche Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%
Management | Tranche Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%
Management | Tranche Eight
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%
Management | Tranche Nine
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		8.33%

Equity Incentive Plans - Rest_2

Equity Incentive Plans - Restricted Stock - Activity (Details)	12 Months Ended
	Jun. 30, 2023 $ / shares shares
Restricted Stock | Aytu 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares) | shares	80,373
Granted (in shares) | shares	6,825
Vested (in shares) | shares	(42,434)
Forfeited/Cancelled (in shares) | shares	(6,689)
Unvested outstanding, ending balance (in shares) | shares	38,075
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 148.91
Granted (in dollars per share) | $ / shares	3.79
Vested (in dollars per share) | $ / shares	126.98
Forfeited/Cancelled (in dollars per share) | $ / shares	135.66
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 142.20
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares) | shares	8,500
Vested (in shares) | shares	(3,537)
Unvested outstanding, ending balance (in shares) | shares	4,963
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 25.88
Vested (in dollars per share) | $ / shares	26.26
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 25.62

Equity Incentive Plans - Rest_3

Equity Incentive Plans - Restricted Stock - Additional Information (Details) - Restricted Stock - Non-plan - $ / shares	Jan. 17, 2022	Jun. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		4
Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	5,000
Granted, weighted average grant date fair value (in dollars per share)	$ 27
Management | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Management | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Management | Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Management | Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Management | Tranche Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Management | Tranche Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Management | Tranche Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Management | Tranche Eight
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%
Management | Tranche Nine
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	8.33%

Equity Incentive Plans - Unreco

Equity Incentive Plans - Unrecognized Compensation Costs (Details) $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($)
Share-Based Payment Arrangement, Option
Unrecognized compensation costs
Unrecognized compensation costs, options	$ 0.1
Unrecognized compensation costs, period for recognition	2 years 2 months 12 days
Restricted Stock | Aytu 2015 Plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 3.6
Unrecognized compensation costs, period for recognition	2 years
Restricted Stock | Non-plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.4
Unrecognized compensation costs, period for recognition	1 year 6 months 21 days
Restricted Stock Units (RSUs)
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.1
Unrecognized compensation costs, period for recognition	1 year 7 months 6 days

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-based Compensation Expense (Details) $ in Thousands		12 Months Ended
	Dec. 19, 2022 USD ($)	Jun. 30, 2023 USD ($) item	Jun. 30, 2022 USD ($)
Stock-based compensation expense
Total share-based compensation expense		$ 6,046	$ 5,248
Cost of Sales
Stock-based compensation expense
Total share-based compensation expense		28	31
Research and Development Expense
Stock-based compensation expense
Total share-based compensation expense		30	536
Selling and Marketing Expense
Stock-based compensation expense
Total share-based compensation expense		23	24
General and Administrative Expense
Stock-based compensation expense
Total share-based compensation expense		$ 5,965	$ 4,657
Restricted Stock | Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members
Stock-based compensation expense
Accelerated unvested shares, former board members, number | item		2
Total share-based compensation expense		$ 1,500
Restricted Stock | Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants
Stock-based compensation expense
Stipulation of compromise and settlement, board members, percentage of 2021 grants rescinded (as a percent)	25%
Total share-based compensation expense	$ 600

Warrants - Stock Issued (Detail

Warrants - Stock Issued (Details) - shares	Jun. 08, 2023	Mar. 07, 2022
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)		151,500
Securities Purchase Agreement, 2023, Private Offering, June 2023
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	1,743,695

Warrants - General Information

Warrants - General Information (Details) $ / shares in Units, $ in Millions	Jun. 08, 2023 USD ($) $ / shares shares	Jan. 06, 2023	Aug. 11, 2022 D $ / shares shares	Mar. 07, 2022 $ / shares shares	Jan. 26, 2022 $ / shares	Jun. 30, 2023 D $ / shares	Nov. 30, 2022 $ / shares	Oct. 25, 2022 $ / shares	Sep. 07, 2022	Aug. 31, 2022 $ / shares
Class of Warrant or Right [Line Items]
Stock split, conversion ratio		0.05
Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares) | shares				151,500
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares				$ 0.002
Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares) | shares				333,300
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares				1.1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares				$ 26
Class of warrant or right, date from which warrants or rights exercisable				Sep. 07, 2022
Warrants and rights outstanding, term				5 years					5 years
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares				$ 24.20				$ 8.60
Class of warrant or right, date from which warrants or rights exercisable				Mar. 07, 2022
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares					$ 24.20
Class of warrant or right, date from which warrants or rights exercisable					Jan. 26, 2022
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable			Aug. 11, 2022
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares) | shares			87,500
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares			1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares			$ 0.02							$ 0.001
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares) | shares			1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares			1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares			$ 8.60			$ 3.30	$ 2.32
Warrants and rights outstanding, term			5 years
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, 20 consecutive trading day period preceding 16th trading day, lowest trading days (in days) | D			5			5
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, consecutive trading days preceding 16th trading day (in days) | D			20
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario one			5
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario two (in dollars per share) | $ / shares			$ 2.32
Class of warrant or right, exercise price adjustment, maximum shares (in shares) | shares			2,325,581
Class of warrant or right, exercise price adjustment, equity offering, common stock price lower than warrant exercise price prior to 2nd anniversary of Stock Combination Event, adjusted exercise price (in dollars per share) | $ / shares			$ 2.32
Warrants to Purchase Common Stock, Liability Classified, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Jun. 08, 2023
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares) | shares	430,217
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 0.0001
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share) | $ / shares	1.5899
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	0.0001
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 1.59
Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares) | shares	2,173,912
Warrants and rights outstanding, term	5 years
Class of warrant, term of expiration after closing price of common stock	30 days
Class of warrant or right, percentage of exercise price equaling common stock	200%
Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares) | shares	2,173,912
Warrants and rights outstanding, term	5 years
Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA	30 days
Adjusted earnings before interest, taxes, depreciation, and amortization | $	$ 12

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Details) - Warrants to Purchase Common Stock - $ / shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Class of Warrant or Right [Line Items]
Outstanding, number of warrants (in shares)	434,328
Warrants issued (in shares)	6,028,331
Warrants exercised (in shares)	(87,500)
Warrant adjusted (in shares)	181,461
Warrants expired (in shares)	(18,568)
Outstanding, number of warrants (in shares)	6,538,052	434,328
Outstanding, weighted average remaining contractual life	4 years 8 months 15 days	4 years 9 months 18 days
Warrants issued, weighted average remaining contractual life	5 years
Warrants exercised, weighted average remaining contractual life	5 years
Warrant adjusted, weighted average remaining contractual life	3 years 10 months 24 days
Weighted Average
Class of Warrant or Right [Line Items]
Outstanding, exercise price (in dollars per share)	$ 92.60
Warrants issued (in dollars per share)	1.61
Warrants exercised (in dollars per share)	0.02
Warrant adjusted (in dollars per share)	5.04
Warrants expired (in dollars per share)	2,011.56
Outstanding, exercise price (in dollars per share)	$ 4.42	$ 92.60

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) $ in Millions	12 Months Ended
	Jun. 30, 2023 USD ($) plan	Jun. 30, 2022 USD ($)
Employee Benefit Plan
Number of employee benefit plan | plan	2
Neos Plan
Employee Benefit Plan
Employee benefit plan contribution		$ 0.4
Neos Plan | First 3% Contribution by Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	100%
Percentage of employees' salary with employer matching contribution	3%
Neos Plan | Next 4% and 5% Contribution by Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	50%
Neos Plan | Next 4% Contribution by Employees
Employee Benefit Plan
Percentage of employees' salary with employer matching contribution	4%
Neos Plan | Next 5% Contribution by Employees
Employee Benefit Plan
Percentage of employees' salary with employer matching contribution	5%
Aytu Plan
Employee Benefit Plan
Employee benefit plan contribution	$ 0.2	$ 0.2
Aytu Plan | 6% Contribution By Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	50%
Percentage of employees' salary with employer matching contribution	6%
Aytu Biopharma Employee Retirement Plan
Employee Benefit Plan
Employee benefit plan contribution	$ 0.7
Aytu Biopharma Employee Retirement Plan | First 3% Contribution by Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	100%
Percentage of employees' salary with employer matching contribution	3%
Aytu Biopharma Employee Retirement Plan | Next 4% and 5% Contribution by Employees
Employee Benefit Plan
Percentage employer matches of employee's contribution	50%
Aytu Biopharma Employee Retirement Plan | Next 4% Contribution by Employees
Employee Benefit Plan
Percentage of employees' salary with employer matching contribution	4%
Aytu Biopharma Employee Retirement Plan | Next 5% Contribution by Employees
Employee Benefit Plan
Percentage of employees' salary with employer matching contribution	5%

Commitments and Contingencies -

Commitments and Contingencies - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended
	May 12, 2022 USD ($)	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 10,420	$ 13,051
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number | agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements		$ 3,000
Fixed payment arrangements, quarterly payment amount, payments, number | payment								6
Fixed payment arrangements, quarterly payment amount								$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, minimum						100			$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements						$ 6,600
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Issues, fixed payment arrangements	$ 7,600

Commitments and Contingencies_2

Commitments and Contingencies - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	12 Months Ended
	Jun. 30, 2023 USD ($) item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item	70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit	$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount	2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation	3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount	$ 40,000,000

Commitments and Contingencies_3

Commitments and Contingencies - Contingent Consideration Liability (Details) - Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments - USD ($) $ in Millions		12 Months Ended
	May 12, 2022	Jun. 30, 2022
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period	$ 8.5
Contingent consideration other than from business combination, gain (loss) for change in fair value during period		$ 0.9

Commitments and Contingencies_4

Commitments and Contingencies - Product Contingent Liability (Details) - Product Contingent Liability, Novalere, FlutiCare $ in Thousands	Jun. 30, 2023 USD ($)	Feb. 28, 2015 USD ($) payment
Other Commitments [Line Items]
Product contingent liability, additional payments, number, certain sales achieved | payment		5
Product contingent liability, additional payments, amount, certain sales achieved		$ 500
Product contingent liability, milestone, payment	$ 0

Commitments and Contingencies_5

Commitments and Contingencies - Earn Out Payments (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Apr. 12, 2021
Commercial Global License Agreements, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, milestone, maximum earn-out, cash and common stock		$ 67,500
License agreement, milestone payment paid, cash and common stock	$ 4,000
Issuance of common stock related to milestone payment (in shares)	109,447
License agreement, milestone payment paid, cash	$ 2,600
Commercial Global License Agreement, Denovo Biopharma LLC, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, annual maintenance fee		25
License agreement, license option fee		600
License agreement, escalating royalties, maximum		101,700
Commercial Global License Agreement, Johns Hopkins University, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, minimum annual royalties, low end of range		5
License agreement, minimum annual royalties, high end of range		$ 20
License agreement, royalties, percentage of net product sales (as a percent)		3%
License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum		$ 1,600

Commitments and Contingencies_6

Commitments and Contingencies - Operating Lease (Details) - Operating Lease Agreement	1 Months Ended
	May 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lessee, operating lease, term of contract	5 years 6 months
Average undiscounted minimum monthly rent payments	$ 15,500
Lessee, operating lease, renewal term	5 years

Commitments and Contingencies_7

Commitments and Contingencies - Legal Matters (Details) - Sabby Litigation	Feb. 22, 2023 shares
Sabby Volatility Warrant Master Fund Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Litigation case, class of warrant or right, number of securities called by warrants or rights	312,908
Number of warrants issued to purchase shares (in shares)	575,000
Walleye Opportunities Master Fund Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Litigation case, class of warrant or right, number of securities called by warrants or rights	54,146
Number of warrants issued to purchase shares (in shares)	100,000

License Agreements (Details)

License Agreements (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2020	Oct. 31, 2017	Feb. 29, 2016
Licensing Agreement, Cedars-Sinai Medical Center, Healight
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, term, after the first bona fide commercial sale of such licensed product in a country	10 years
License agreement, initial license fee paid	$ 0.3
License agreement, patent prosecution fees paid	$ 0.1
Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum			$ 1
License Agreement, 2017, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum		$ 1

Segment Information - General I

Segment Information - General Information (Details) - segment	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Segment Information - Impairmen

Segment Information - Impairment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Asset Impairment Charges [Abstract]
Impairment loss	$ 5,705	$ 75,458
Production Related Impairments or Charges [Abstract]
Inventory write-down	2,351	2,186
Rx
Asset Impairment Charges [Abstract]
Impairment loss	2,600	64,600
Consumer Health Segment
Asset Impairment Charges [Abstract]
Impairment loss	3,000	$ 10,800
Production Related Impairments or Charges [Abstract]
Inventory write-down	$ 2,100

Segment Information - Select Fi

Segment Information - Select Financial Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenues [Abstract]
Revenue from contract with customer	$ 107,399	$ 96,669
Loss from operations	(17,065)	(109,906)
Depreciation and amortization	7,387	9,378
Impairment and write-off expense	7,824	75,458
Stock-based compensation expense	6,046	5,248
Rx
Revenues [Abstract]
Revenue from contract with customer	73,799	61,121
Loss from operations	(7,358)	(92,441)
Depreciation and amortization	6,271	7,821
Impairment and write-off expense	2,730	64,649
Stock-based compensation expense	5,722	5,190
Consumer Health Segment
Revenues [Abstract]
Revenue from contract with customer	33,600	35,548
Loss from operations	(9,707)	(17,465)
Depreciation and amortization	1,116	1,557
Impairment and write-off expense	5,094	10,809
Stock-based compensation expense	$ 324	$ 58